

# Index

Page references followed by b, f, and t denote boxes, figures, and tables, respectively.

- A**
- Abdominal laparotomy, acquisition of mouse tumor biopsies through (protocol), 440–449
- discussion, 446–449
  - evaluation of tumor location and vascularity, 447
  - KPC model of pancreatic ductal adenocarcinoma (case study), 446–447
  - mouse anesthesia, 447–448
  - outcome, 448–449, 448f
  - materials, 440–442, 442f
  - method, 442–446
    - advance preparation, 442–443, 443f
    - animal preparation, 443–444
    - postoperative care, 445–446
    - surgery, 444–445, 444f
  - troubleshooting, 446
- Acids
- disposal of, 501
  - safe handling of, 500, 503
- ACK (ammonium-chloride-potassium) lysis buffer, 385, 397
- actin* promoter, 145
- Acute lymphoblastic leukemia (ALL), 257, 257t
- Acute myelogenous leukemia (AML)
- IL27 efficacy testing, 258
  - NSG mice with human PDX tumors as models for testing drug efficacy, 257, 257t
  - tumor-initiating cells (TICS), 260
- Acute promyelocytic leukemia (APL), 6–7, 7f, 436
- genetic heterogeneity of, 456
  - sequence of cancer genome of mice and humans, 493–494
- Adams, Jerry, 3, 22
- ADC (apparent diffusion coefficient), 329, 341
- Adenomatous polyposis coli (APC) tumor suppressor. *See Apc*
- Adenovirus
- gene delivery, 111–112, 458
  - in vivo delivery of lenti-Cre or adeno-Cre into mice using intranasal instillation (protocol), 119–121
  - materials, 119–120
  - method, 120
  - recipe, 121
  - troubleshooting, 120–121
- Adenovirus with Flp recombinase (Ad-FlpO), 40
- ADT (androgen deprivation therapy), 11
- Adult stem cells, culturing from mouse small intestinal crypts (protocol), 417–421
- discussion, 419–420
  - materials, 417–418
  - method, 418–419
    - culture of isolated crypts, 418–419
    - dissociation and culture of single cells, 419
    - isolation of crypts, 418
    - recipes, 420
- Afatiniib, 436
- Akt, 206
- Pten* conditional knockout mouse models, 41–42
  - reporters and, 320
  - Snail* expression induced by, 135
  - tissue recombination models and, 231, 233f, 234
- Albumin* promoter, 145
- Alb-Cre, 42, 43
- Alcohol fixatives, 298, 298t
- ALL (acute lymphoblastic leukemia), 257, 257t
- Allografts, 9
- All-trans retinoic acid (ATRA), 7, 436
- $\alpha$ -crystallin lens-specific promoter, 94
- $\alpha$ -sk-actin promoter, 159
- American Type Culture Collection (ATCC), 503
- Amidoazotoluene, 52
- 7-amino-actinomycin D (7-AAD), 387
- AML. *See* Acute myelogenous leukemia
- Anatomic pathology. *See* Pathology
- Androgen deprivation therapy (ADT), 11
- Anesthesia
- for imaging, 327, 336, 337, 340, 344
  - overview of, 447
  - for surgery, 443, 447–448
- Animals, humane treatment of, 501
- Antibodies, used for immunohistochemical assessment of immune cells, 391
- AOM (azoxymethane), 56
- Apc*
- analysis in germline mouse models of cancer, 30
  - conditional knockout mouse models, 42–43
  - shRNA targeting of, 194
  - Sleeping Beauty* mutagenesis and, 179
- Aperio Spectrum (eSlide Manager) database, 468
- APL. *See* Acute promyelocytic leukemia
- Apoptosis, immunohistochemical markers of, 433t
- Apparent diffusion coefficient (ADC), 329, 341
- Arabidopsis* light oxygen voltage (LOV) domain-containing proteins, 111
- Arf*
- deletion of, 204
  - lung cancer and, 65
  - shRNA targeting of, 198
  - skin cancer and, 55
- Aristotelian logic, 469
- Aromatic amines, as carcinogens, 53
- Arteaga, Carlos, 351
- As<sub>2</sub>O<sub>3</sub>, 6–7, 8
- ATCC (American Type Culture Collection), 503
- Athymic *FoxI<sup>tm</sup>* (nude) mice, 254, 255t
- ATM kinase, 206
- ATP, bioluminescence and, 343, 345
- ATRA (all-trans retinoic acid), 7, 436
- Atypical alveolar hyperplasias, 96
- Autoclave safety, 500
- Avertin, 120, 249
- Avertin (20 mg/mL) (recipe), 121
- Avian leukosis virus, 22
- Avian sarcoma leukosis virus subgroup A (ASLV-A), 155. *See also* RCAS (replication-competent avian-leukosis virus)
- Avidin–biotin complex (ABC) technique, immunohistochemistry staining of mouse tissues using the (protocol), 304–307
- discussion, 306–307
  - material, 304–305
  - method, 305–306
  - recipes, 307
  - troubleshooting, 306
- Azo dyes, as carcinogens, 52
- Azoxymethane (AOM), 56
- B**
- Bacteria
- biological safety procedures, 502–503
  - shipping requirements, 503
- Bacteriophytochrome, 313
- Bannayan-Zonana syndrome (BZS), 29, 41
- Bases
- disposal of, 501
  - safe handling of, 500, 503
- Bayh-Dole Act, 4
- B-cell freezing medium (recipe), 213
- B-cell medium (recipe), 213, 222
- BclX-L, 349
- Bcr-Abl* transgene, 133, 134, 206
- Benzo[a]pyrene, 52
- $\beta$ -catenin
- APC* conditional knockout models and, 42–43
  - in hepatocellular tumors, 132
- $\beta$ -galactosidase reporter gene, 146
- in T<sub>1</sub>-weighted imaging, 316
- $\beta$ 1-integrin, 349
- $\beta$ -lactoglobulin (*BLG*) promoter, 35, 37
- $\beta$ -naphthoflavone, 111
- bFGF inhibitors, 9
- BFS growth medium (recipe), 242, 246
- Biological safety procedures, 502–503
- Bioluminescence imaging (BLI)
- analysis of retrovirus-transduced cells with, 367
  - bioluminescent reactions, 311f
  - data analysis and presentation, 346
  - key features, 311–312
  - overview, 310–312, 311f, 313f, 330–331, 330f
  - properties of luciferin, 345
  - quantitative bioluminescence imaging of mouse tumor models (protocol), 343–346
  - discussion, 345–346

## Index

- Bioluminescence imaging (BLI) (*Continued*)  
  materials, 343–344  
  method, 344  
  recipe, 346  
  troubleshooting, 344–345  
  routes of luciferin injection, 345–346  
  strengths and limitations of, 326f  
  as tool for imaging, 345
- Biomarker discovery, 479–483  
  assays of tumor-derived nucleic acids, 482  
  blood and plasma collection for molecular profiling, 483  
  circulating tumor cells, 483  
  GEMMs as source of circulating cancer markers, 480  
  GEMMs metabolic profiling, 480–481  
  immune response to tumor development and, 481–482  
  omics approaches for, 481b  
  value of GEMMs for, 479–480
- Biopsy  
  acquisition of mouse tumor biopsies through  
    abdominal laparotomy (protocol), 440–449  
    discussion, 446–449  
    evaluation of tumor location and vascularity, 447  
    KPC model of pancreatic ductal adenocarcinoma (case study), 446–447  
    mouse anesthesia, 447–448  
    outcome, 448–449, 448f  
    materials, 440–442, 442f  
    method, 442–446  
    advance preparation, 442–443, 443f  
    animal preparation, 443–444  
    postoperative care, 445–446  
    surgery, 444–445, 444f  
    troubleshooting, 446  
  in therapeutic studies, 434
- Biopsy forceps, 441, 442f  
Biopsy punch, 445  
Bishop, Mike, 6  
Bladder cancer  
  industry-related, 52–53  
  patient-derived xenograft (PDX), 261–262, 271
- Blanpain, Cedric, 350  
BLI. *See* Bioluminescence imaging  
Blood and plasma collection for molecular profiling, 483
- Bmi-1*, 206  
Body temperature support during imaging, 327  
Bone marrow, isolation of HSCs from, 211  
Bovine keratin 5 promoter, 146  
Bradley, Allen, 5  
BRAF  
  knock-in models of cancer, 92t  
  melanomas and, 458
- Brain tumors induced by SV40 large T-antigen, 18–20
- BRCA1* conditional mutant mouse models, 31, 34–37, 34f, 35f  
*BRCA2* conditional mutant mouse models, 31, 37  
BreakDancer (software tool), 492
- Breast cancer  
  cleared mammary fat pad transplantation assay for mammary epithelial organogenesis (protocol), 247–251  
  cleared MFP transplantation, 249–250, 250f  
  dissociation of mouse mammary tissue, 248–249, 249f  
  materials, 247–248  
  method, 248–250, 249f, 250f  
  recipes, 250–251  
  combinational therapy, 9  
  conditional knock-out mouse models, 34–40, 36t  
    *BRCA1* conditional mutant mouse models, 34–37, 34f, 35f  
    *BRCA2* conditional mutant mouse models, 37  
    *p53* LFS (loss-of-function) mouse models, 40  
  mammary fat pad as an orthotopic site for studying, 229–230  
  in *MMTV-Myc* mice, 4  
  models of metastasis, 349  
  mouse mammary tumor virus (MMTV) models, 20–21  
  reverse transcriptase PCR (RT-PCR), for cancer biomarker discovery, 483  
  sequence cancer genome of mice and humans, 493  
  tetracycline-regulated model system, 129, 131t  
  TNBC (triple-negative breast cancer), 37  
  Breast cancer metastasis suppressor 1, 349
- Brinster, Ralph, 3, 5, 7, 18, 19, 22  
Bronchioalveolar adenoma/carcinoma (BAC), pathology of, 282
- Bryan RSV, 156  
BSA coating solution (recipe), 250  
Buprenorphine, 440, 443, 444, 446  
Burkitt's lymphoma, 22, 204  
Burrows-Wheeler Aligner (software), 492  
BZS (Bannayan-Zonana syndrome), 29, 41
- C**
- caELMIR (Cancer electronic Laboratory Management Information and Retrieval), 467, 468, 470–477  
  background of, 467, 468  
  structure of, 470–477  
    Experiment, 471, 472f, 473, 473f  
    pathology, 473  
    slide report, 473, 476f  
    Specimen, 473, 474f, 475f  
    spreadsheet report, 473, 477f  
    Study, 471, 471f, 472f
- CAGGS promoter  
  CAGGS promoter-driven FLP, 194  
  for overexpression of an oncogene, 97  
  *piggyBac* transposons and, 180  
  *Sleeping Beauty* transposons and, 174, 175t, 176
- CA125 marker for ovarian cancer, 480  
CA19-9 marker for pancreatic cancer, 480  
*Camk2a* promoter, 133  
Camk2a-tTA model, 133  
Camthotecin, 206
- Cancer. *See also* Chemical carcinogenesis  
  as environmental disease, 52  
  genetic predisposition, 52
- Cancer electronic Laboratory Management Information and Retrieval. *See* caELMIR
- Cancer genome  
  current ICGC and TCCA projects, 490t–491t  
  mouse and human compared, 489–496  
  sequencing for cancer genome analysis  
    DNA sequencing, 492  
    emerging technologies, 493  
  experimental design, 495–496, 495f  
  RNA sequencing, 492  
  sequencing to find DNA-protein interactions, 493  
  single-cell sequencing, 493
- The Cancer Genome Atlas (TCGA), 489, 490t–491t, 493, 495
- Cantley, Lewis C., 10, 11  
Capecchi, Mario R., 5, 33  
CAR (chimeric antigen receptor), 258  
Carboxyfluorescein succinimidyl ester (CFSE), 400
- Carcinogens. *See also* Chemical carcinogenesis  
  carcinogen bioassay, 51, 53–54, 57  
  carcinogen-induced models, 9–10  
  tetracycline-regulated systems and, 137  
  early studies and the use of animals to identify, 52–53
- Castle, William, 1  
Catalog of Somatic Mutations in Cancer (COSMIC), 178
- Caveolin-1, 349  
*C.B17-Prkdc<sup>scid</sup> (scid)* mice, 254–255, 255t  
CCL20, 258  
CCR2b, 258  
CCSP (Clara cell secretory protein) promoter, in tetracycline-regulated model system, 131
- CD8, 258  
CD34<sup>+</sup>, 258, 261  
CD47, 255, 257  
CD133, 260  
CD271, 260  
CD40 agonist, 437  
*Cdkn2a* locus, ablation of, 196  
CDKN1B (cyclin-dependent kinase inhibitor p27), 55–56
- cDNA  
  in conditional knock-in alleles, 94f, 95  
  sequencing pools of fragments, 492
- CD2 promoter, 146  
CEA marker for colon cancer, 480  
Cell surface markers, for immune cell populations, 387t
- Center for Genomic and Translational Phenotyping (CGTP)  
  Image Archive Aperio  
  database, 471
- Center for Genomic Pathology, 287  
Central nervous system cancer, tetracycline-regulated model system for, 131t, 133
- CEST (chemical exchange saturation transfer), 315–316
- Cetuximab, 436  
CFSE (carboxyfluorescein succinimidyl ester), 400
- CGTP (Center for Genomic and Translational Phenotyping) Image Archive  
  Aperio database, 471
- Chemical carcinogenesis, 51–67  
  carcinogen bioassay, 51, 53–54, 57  
  in experimental cancer research, 54–55  
  models  
    applications of, 51  
    common models, 57–58, 57t  
    future of, 58  
    genetically engineered mouse models (GEMMs), 51–52, 55–56, 57–58  
    to identify genetic modifiers of cancer risk, 56–57

- protocols
    - induction of colon cancer with
      - 1,2-dimethylhydrazine, 66–67
      - discussion, 67
      - materials, 66
      - method, 66–67
    - induction of liver tumors with *N*-ethyl-*N*-nitrosourea or *N*-nitrosodimethylamine, 61–62
      - discussion, 62
      - materials, 61
      - method, 62
    - induction of lung tumors with urethane,
      - 63–65, 64f
      - discussion, 64–65, 64f
      - materials, 63
      - method, 63–64
  - Chemical exchange saturation transfer (CEST), 315–316
  - Chemicals, properties of common hazardous, 503–504
  - Chemical safety assessment, 53–54
  - Chimera
    - chimeric tumor models, 203–226
      - synergic transplants with modified chimeric hematopoietic tumors (protocol), 219–223
    - multiallelic nongermine GEMM generation via ES cell rederivation, 198
  - Chimeric antigen receptor (CAR), 258
  - ChIP-chip, 493
  - ChIP-Seq, 493
  - Chk2 kinase, 206
  - Chronic myelogenous leukemia (CML), 261
  - Circadian effects, 85
  - Circulating tumor cells (CTCs)
    - as diagnostic markers, 483
    - in genetically modified models of metastasis, 351–352
  - Cisplatin, 436
  - Clara cell secretory protein (CCSP) promoter, in tetracycline-regulated model system, 131
  - Clevers, Hans, 350
  - Clinical trials. *See* Trials
  - c-Met*, in hepatocellular tumors, 132
  - CML (chronic myelogenous leukemia), 261
  - cMyc, 22, 147
  - cMycER<sup>TAM</sup>, 146–147
  - Co-Clinical paradigm, 13f
  - Co-Clinical Trial Project, 10–12, 10f, 11f, 461
  - Coclinical trials
    - data integration and evaluations, 465–466, 465b
    - GEMMs use in, 455–460
      - designing trials, 459–460
      - goals for clinical efforts in GEMMs, 457b
      - optimizing model use trials, 456–457, 456b
      - selecting appropriate model for analyses, 457–459
    - infrastructure needs for, 461–466
    - structured reporting in pathology for, 467–478
      - caELMIR example, 467, 468, 470–477
        - Experiment, 471, 472f, 473, 473f
        - pathology, 473
        - slide report, 473, 476f
        - Specimen, 473, 474f, 475f
        - spreadsheet report, 473, 477f
        - Study, 471, 471f, 472f
      - controlled vocabulary, 469–470
      - structured reports, 468–469
- Col1A* locus, 97
- Col1A1* locus, Flp/FRT homing cassettes, 194, 195f
- Colenterazine, 310, 311f, 312
- Collaborative Cross
  - overview, 73
  - using to study role of genetic diversity in cancer-related phenotypes (protocol), 81–87
    - carcinogen/pathogen/cancer-related physiology (example), 82, 83f
    - discussion, 84–85
    - genetically engineered mouse model (example), 82, 83f, 84
    - materials, 81–82
    - method, 82–84, 83f
    - syngeneic tumor graft model (example), 83f, 84
- Collaborative Cross Consortium, 73
- Collagenase solution (recipe), 251
- Collagenase type I, 241, 244
- Collagenase type IV, 398, 405
- Collagen plugs, preparation of prostate cell recombinants in, 245
- Collagen solution (recipe), 406
- Collagen type II  $\alpha 1$  (*Col2a1*) promoter, 146
- Colon cancer
  - CEA marker for, 480
  - induction of colon cancer in mice with 1,2-dimethylhydrazine (protocol), 66–67
  - modeling using *Sleeping Beauty* transposon-based insertional mutagenesis, 179
  - tetracycline-regulated model system, 131t, 132
- Combinational therapy, GEMM use in studies of, 8–9
- Compara (software tool), 494
- Comparative Anatomy and Histology: A Mouse and Human Atlas* (Treuting and Dintzis), 285, 295
- Complete medium for metastatic studies (recipe), 362, 373
- Computed tomography (CT)
  - overview, 327–328
  - strengths and limitations of, 326t
- Conditional gene mutation in mice, 105–124
  - breeding schemes, 109f
  - overview, 105
  - protocols, 116–124
    - in vivo delivery of lenti-Cre or adeno-Cre into mice using intranasal instillation, 119–121
      - materials, 119–120
      - method, 120
      - recipe, 121
      - troubleshooting, 120–121
    - producing and concentrating lenti-Cre for mouse infections, 116–118
      - materials, 116–117
      - method, 117–118
    - whole-mount X-gal staining of mouse tissues, 122–124
      - materials, 122–123
      - method, 123
      - recipes, 124
      - troubleshooting, 123
  - site-specific recombinases, 106–108
    - acute regulation of Cre activity, 111
    - dual recombinase technology, 112–113
    - transgenic expression of Cre, 108, 109f, 110f, 110t
  - validation of Cre activity, 112
    - viral delivery of Cre, 111–112
- Conditional knock-in mouse models, 93–95
  - maintenance of wild-type gene expression, 95
  - regulating recombination/activation, 95–97
  - removable transcriptional terminal stop elements, 93–95, 94f
- Conditional knockout mouse models of cancer, 33–49, 36t, 38t–39t
  - APC models, 42–43
  - familial breast cancers, 34–40, 36t
    - BRCA1 conditional mutant mouse models, 34–37, 34f, 35f
    - BRCA2 conditional mutant mouse models, 37
    - p53 LFS (loss-of-function) mouse models, 40
  - p53 models, 40
  - Pten models, 41–42
  - Rb models, 40–41
  - SMAD4 models, 43–44
- Conditional site-specific recombinase system, 145
- Controlled vocabulary, 469–470
- Cooperative cancer research trials, structured reporting in pathology for, 467–478
- Cory, Suzanne, 3, 22
- COSMIC (Catalog of Somatic Mutations in Cancer), 178
- Costantinin, Franklin, 2
- COUP transcription factor II (COUP-TFII), 44
- Cowden syndrome, 29, 41
- CpG methylation, 179, 482
- Cre-dependent transgene reporters, 317–318
- CreER, 111
- Cre-ER<sup>T2</sup>, 95–97, 146–147
- Cre-loxP recombinase system
  - conditional gene mutation in mice, 106–113
  - conditional knockout mouse models of cancer, 33, 35, 35f, 41–44
    - drawbacks of, 107
    - efficacy of recombination, 107
    - in knock-in models of cancer, 93–97
- Cre recombinase, 106–113
  - acute regulation of Cre activity, 111
  - comparing mice homozygous for floxed allele and Cre transgene to sibling controls on a mixed background, 78f, 79
  - Cre-ER<sup>TAM</sup>, 145, 146
  - drivers in models in pre-/co-/postclinical trials, 458
  - dual recombinase technology, 112–113
  - iCre (improved Cre), 107
  - inducible expression, 95
  - in knock-in alleles, 91f, 93–97
  - mechanism of recombination, 106f
  - recognition sequences and mechanisms of recombination, 106f
  - recognition sites, 106–108, 106f, 107t, 113
  - shRNA delivery and, 192, 193
  - Sleeping Beauty* transposons and, 174, 178, 181–182
  - split, 111
  - in tetracycline-regulated systems, 127–128, 128f
  - tissue-specific expression, 96, 110f, 110t
  - transgenic expression of Cre, 108, 109f, 110f, 110t
  - validation of Cre activity, 112
  - viral delivery of Cre, 96, 111–112

## Index

- Croton oil, 54  
Cryopreservation of mouse lymphocytes and immune cells, 485–486  
CT. *See* Computed tomography  
Culturing mouse tumor cells, 401–426  
  applications of 3D culture models, 402t  
  creating primary cell lines from lineage-labeled mouse-models (protocol), 408–411  
  discussion, 410–411  
  materials, 408–409  
  method, 409–410  
  recipes, 411  
  troubleshooting, 410  
  culturing adult stem cells from mouse small intestinal crypts (protocol), 417–421  
  discussion, 419–420  
  materials, 417–418  
  method, 418–419  
  culture of isolated crypts, 418–419  
  dissociation and culture of single cells, 419  
  isolation of crypts, 418  
  recipes, 420  
  culturing primary mouse pancreatic ductal cells (protocol), 404–407  
  materials, 404–405  
  method, 405–406  
  culturing and passaging cells, 406  
  single-cell suspension preparation, 405  
  recipes, 406–407  
  troubleshooting, 406  
organotypic culture of untransformed and tumorigenic primary mammary epithelial cells (protocol), 412–416  
  discussion, 414  
  materials, 412–413  
  method, 413–414  
  recipes, 415  
  troubleshooting, 414  
questions to ask before establishing a culture, 401–402  
three-dimensional organotypic culture of stratified epithelia (protocol), 422–426  
  discussion, 424  
  materials, 422–423  
  method, 423–424  
  recipes, 425–426  
  troubleshooting, 424  
Cutting devices, safe handling of, 501  
Cyclin D, 44  
Cyclin-dependent kinase inhibitor p27 (CDKN1B), 55–56  
Cytochrome P450 1A1 (CYP1A1) promoter, 111  
Cytomegalovirus promoter, 94, 145
- D**
- Data  
  infrastructure considerations for curation of data, 465b  
  integration, 465–466  
  sharing (*see* Sharing scientific data)  
Data tables, 468  
DBD (DNA-binding domain), 98, 99f  
DCE-MRI (dynamic contrast-enhanced MRI), 330
- Dct* (dopachrome tautomerase) promoter, in tetracycline-regulated model system, 133, 135  
DEN. *See* *N*-nitrosodiethylamine (DEN)  
Department of Health, Education, and Welfare (HEW), U.S., 503  
Description logic, 470  
DF1 (chicken fibroblast cell line), 155, 159  
  generation of high-titer RCAS virus from DF1 chicken fibroblasts (protocol), 163–168  
Dibenz[a,h]anthracene, 52  
Dicer, 188  
Diffusion-weighted imaging (DWI), 329, 341  
Digestion buffer for mammary glands (recipe), 415  
Digestion solution for tissue dissociation (recipe), 362  
4-dimethyl-aminoazobenzene, 52  
7,12-dimethylbenz[a]anthracene (DMBA), 54, 55, 56  
1,2-dimethylhydrazine (DMH), 56, 66–67  
Disease  
  general disease processes, 275t  
  ontogeny of, 274f  
Disposal  
  general cautions, 499–501  
  of laboratory waste, 501  
DMBA (7,12-dimethylbenz[a]anthracene), 54, 55, 56  
DMBA/TPA skin cancer protocol, 55, 57  
DMH (1,2-dimethylhydrazine), 56, 66–67  
DMN (*N*-nitrosodimethylamine), early animal studies on, 53  
DNA, processing genomic for high-throughput sequencing  
  digestion with restriction enzymes, 176  
  shearing of DNA, 176–177  
DNA assays, 482  
DNA-binding domain (DBD), 98, 99f  
DNA damage, immunohistochemical markers of, 433t  
DNA-protein interactions, sequencing to find, 493  
DNA sequencing  
  for cancer genome analysis  
  cDNA, 492  
  emerging technologies, 493  
  experimental design, 495–496, 495f  
  mapping software, 492  
  sequencing to find DNA-protein interactions, 493  
  single-cell sequencing, 493  
  comparing mouse and human sequences, 489–496  
  next-generation sequencing (NGS) technologies, 489, 493  
  PCR amplification and sequencing of transposon insertion sites, 176–177, 177f  
Docetaxel, 9, 11–12, 436  
Dopachrome tautomerase (*Dct*) promoter, in tetracycline-regulated model system, 133, 135  
Double-stranded RNA (dsRNA), 188  
Doxorubicin, 436  
Doxycycline, 111, 125–127, 126f, 128f, 182f, 183. *See also* Tetracycline-regulated systems  
Doxycycline-regulated oncogenes for metastasis studies, 352
- Dre recombinase, 107–108, 107t  
Drosha/DGCR8 complex, 188  
Drug resistance. *See* Resistance to cancer therapy  
Drug testing, preclinical, 7–9, 456, 456b  
Drug transporters, 436  
dsRNA (double-stranded RNA), 188  
Dual recombinase technology, 112–113  
DuPont Corporation, 4–5  
Dutasteride, 9, 11  
Dyer, Mike, 29  
Dyes, hazards of, 503  
Dynamic contrast-enhanced MRI (DCE-MRI), 330, 341  
Dynamic contrast enhancement (DyCE), 313  
Dynamic susceptibility MRI, 330
- E**
- E2AER, 147  
E-cadherin, 216  
E2F promoter, 318  
EGFR. *See* Epidermal growth factor receptor  
*elastase* promoter, 23, 132  
Elastase-Ras model, 23  
Electronic media, 467–478  
*Elf5*, 349  
ELISPOT (enzyme-linked immunosorbent spot) assay, 486  
Embelin, 9, 11  
Embryonic stem cells  
  history of use, 4–5  
  homologous recombination in, 4–5  
  rederivation, generation of multiallelic nGEMMs via, 197–198  
*Eμ-myc* lymphoma model, 3–4, 22, 148, 190, 191, 193, 204, 206  
EMT. *See* Epithelial-to-mesenchymal (EMT) transition  
Engelman, Jeffrey, 11  
Enrollment criteria, for therapeutic trials/studies, 431  
Ensembl Genome Browser (software), 494  
ENU. *See* *N*-ethyl-*N*-nitrosourea  
Environmental Protection Agency (EPA), U.S., 501  
Enzyme-linked immunosorbent spot (ELISPOT) assay, 486  
Eosin Y solutions (recipe), 302  
EPA (Environmental Protection Agency), U.S., 501  
Epidermal growth factor receptor (EGFR), 159  
  inhibitors, 131, 134, 432, 436  
  knock-in models of cancer, 92t, 97  
  mutations in lung cancer, 137–138, 452  
  in tetracycline-regulated models, 137–138  
Epithelial cancer, tissue recombination models  
  for study of, 227–251  
  cleared mammary fat pad transplantation assay for mammary epithelial organogenesis (protocol), 247–251  
  dissociated prostate regeneration under the renal capsule (protocol), 243–246  
  preparation of urogenital sinus mesenchymal cells for prostate tissue recombination models (protocol), 240–242  
Epithelial cell adhesion molecule (EpcAM), 483  
Epithelial cells, culturing protocols for

- creating primary cell lines from lineage-labeled mouse-models (protocol), 408–411
    - discussion, 410–411
    - materials, 408–409
    - method, 409–410
    - recipes, 411
    - troubleshooting, 410
  - organotypic culture of untransformed and tumorigenic primary mammary epithelial cells (protocol), 412–416
    - discussion, 414
    - materials, 412–413
    - method, 413–414
    - recipes, 415
    - troubleshooting, 414
  - three-dimensional organotypic culture of stratified epithelia (protocol), 422–426
    - discussion, 424
    - materials, 422–423
    - method, 423–424
    - recipes, 425–426
    - troubleshooting, 424
  - Epithelial-to-mesenchymal (EMT) transition, 135
    - development of, 284–285
    - immunohistochemistry, 283f
    - isolating epithelial and epithelial-to-mesenchymal transition populations from primary tumors by FACS (protocol), 374–376
      - discussion, 376
      - materials, 374–375
      - method, 375–376
    - Rb* conditional mutant mouse models, 41
  - ErbB2* gene, 20, 24
  - ERG, tissue recombination models and, 231, 233f, 234
  - Erlotinib
    - generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mice (protocol), 450–453, 452f
    - maximum tolerated dose (MTD) for, 432 for tumors with EGFR mutations, 138, 432, 436
  - Erlotinib (recipe), 452–453
  - ER<sup>T2</sup>, 144, 146–147, 149
    - Cre-ER<sup>T2</sup>, 95–97, 146–147
    - Sleeping Beauty* transposons and, 181–182, 182f
  - ER<sup>TAM</sup>, 144–149, 151
  - ES cells. *See* Embryonic stem cells
  - 17 $\beta$ -estradiol, 144, 149
  - Estrogen receptor (ER) regulatable system, 143–153
    - CreER, 111
    - ER-fused oncogenes, 146–147
    - ER-fused tumor suppressors, 147–149, 148f
    - future prospects, 149
    - in gene-targeting technology, 144–146, 145f
    - tamoxifen administration to mice (protocol), 151–152
  - Ethyl carbamate. *See* Urethane
  - N*-ethyl-*N*-nitrosourea (ENU)
    - induction of liver tumors in mice with *N*-ethyl-*N*-nitrosourea or *N*-nitrosodiethylamine (protocol), 61–62
    - use to identify lung cancer susceptibility loci, 56
  - ETS family transcription factors, 231
  - Evans, Martin J., 5, 33
  - Experimental cancer research, chemical carcinogenesis in, 54–55
  - Extramedullary hematopoiesis, 282
  - F**
  - Facilities, for translational therapeutic studies, 434–435
  - FACS. *See* Fluorescence-activated cell sorting
  - FACSCanto, 387
  - Familial adenomatous polyposis (FAP), 30
  - "Fancy" mice, 1, 69, 70f
  - Farnesoid X receptor (FXR), 149
  - FDA (Food and Drug Administration) safe harbor, 5
  - FDG-PET, 327–328, 328f, 335–338
  - Ferritin, 315, 315f
  - Fibroblast growth factor 10 (FGF10),
    - overexpression in urogenital sinus mesenchyme (UGSM) cells, 235
  - Field Tested Best Practice, 462, 466
  - 5' splice donor trap, 94f, 95
  - Fixation
    - mouse tissue fixation (protocol), 297–299
      - data for common fixatives, 298t
      - discussion, 298–299
      - fixative choice, 298–299, 298t
      - materials, 297
      - method, 297–298
      - timing and duration of fixation, 299
    - postmortem changes stopped by, 285–286
    - in whole-mount X-gal staining of mouse tissues (protocol), 123
  - Fixative, choosing, 298–299, 298t
  - Flippase. *See* FLP recombinase
  - Flippase recognition target. *See* FRT sites
  - Flk1 promoter, TVA expression using, 160
  - Flotillin-2, 349
  - Flow cytometry
    - analysis of immune cell subsets in tumor-bearing mice (protocol), 384–389
    - analysis of retrovirus-transduced cells in, 367
    - standardization and standard operating procedures for immune assays, 487
  - Floxed allele, 78f, 79, 108
  - Flp-FRT recombinase system
    - conditional gene mutation, 96, 106f, 107, 113
    - conditional knockout mouse models of cancer, 33, 40
    - recognition sequences and mechanisms of recombination, 106f
    - recombinase-mediated cassette exchange, 194
  - Flp recombinase, 106f, 107, 107t, 113
    - drivers in models in pre-/co-/postclinical trials, 458
  - Fluorescence-activated cell sorting (FACS)
    - in enrichment of mammary basal and luminal cells for cell-of-origin metastatic studies (protocol)
      - FACS sorting, 371, 372f
      - staining cells for FACS, 370–371
    - in isolating epithelial and epithelial-to-mesenchymal transition populations from primary tumors by FACS (protocol), 374–376
      - discussion, 376
  - materials, 374–375
  - method, 375–376
  - in multicolor flow cytometric analysis of immune cell subsets in tumor-bearing mice protocol, 386–387, 387t, 388t
- Fluorescence imaging, 312–314, 313f
  - analysis of retrovirus-transduced cells with fluorescence microscopy, 367
  - overview, 331
  - strengths and limitations of, 326f
- Fluorescence minus one (FMO) strategy, 371
- Fluorescence ubiquitination cell cycle indicator (FUCCI), 319
- FMO (fluorescence minus one) strategy, 371
- FokI nuclease, 98, 100
- Folkman, Judah, 23
- Food and Drug Administration (FDA) safe harbor, 5
- Formaldehyde (3%) (recipe), 395
- Formaldehyde (formalin) fixative, 298, 298f, 299, 392
- FRT sites, 106f, 107, 107t, 113
- FUCCI (fluorescence ubiquitination cell cycle indicator), 319
- FuGENE 6, 117
- FXR (farnesoid X receptor), 149
- G**
- $\gamma$ -secretase inhibitor, 196
- Gas containers, safe handling of, 500
- Gastrointestinal stromal tumors (GISTs), 90
- Gaussian kernel convolution (GKC) method, for identification of transposon insertion sites, 177–178
- G-CSF (granulocyte colony-stimulating factor), 260
- Gefitinib, 138
- Geldanamycin, 138
- Gelfoam, to plug biopsy site, 445, 448, 448f
- Gemcitabine, 433, 482
- GEMMs. *See* Genetically engineered mouse models
- Gene expression, facilitation of detection, 97–98
- Gene-targeting technology
  - estrogen receptor (ER) regulatable system in, 144–146, 145f
  - history of, 4
  - "hit and run," 93
- Genetically engineered mouse models (GEMMs). *See also specific models*
  - chemical carcinogenesis, 51–52, 55–56, 57–58
  - nongermline GEMMs
    - accelerating mouse model production using, 196, 197f
    - generation of multiallelic via ES cell rederivation, 197–198
  - preclinical drug testing, 7–9
  - RNAi and, 187–193
  - strengths and weaknesses of models of tissue recombination models for study of epithelial cancer, 231–235
  - tetracycline-regulated system, 125, 133–138
- Genetic modifiers of cancer risk, chemical carcinogenesis models to identify, 56–57
- Genetic screens in transplant models, 206–207
- Genome. *See* Cancer genome
- Genome Analysis Toolkit (software), 492

## Index

- GFP. *See* Green fluorescent protein  
*GH* gene, 18–19  
GISTs (gastrointestinal stromal tumors), 90  
GKC (Gaussian kernel convolution) method, for identification of transposon insertion sites, 177–178  
Gleevec. *See* Imatinib  
Glioblastoma  
  knock-in model of, 97  
  MRI images of, 329f  
Gliomas, RCAS-TVA system models of, 159–160  
Glyoxal fixative, 298, 298t  
Good Laboratory Practice, 464  
Gordon, Jon W., 2  
Granulocyte colony-stimulating factor (G-CSF), 260  
Gr-1<sup>+</sup> cells, isolation of, 398–399, 400  
Green fluorescent protein (GFP)  
  in vivo imaging and, 331  
  in loss-of-function screening in hematopoietic malignancies protocol, 225, 225f  
  in synergetic transplants with modified chimeric hematopoietic tumors protocol, 221–222, 222f  
Gross specimen logic tree, 276f  
G solution (recipe), 407
- ## H
- Hanahan, Douglas, 21, 23  
*Handbook of Carcinogenic Potency and Genotoxicity Databases*, 53  
Haploinsufficient tumor suppression, 56  
Hatch-Waxman exemption, 5  
Hazardous chemicals, properties of common, 503–504  
HBD (hormone-binding domain) fusions, 143–144, 144f, 151  
*Hcr* modifier allele, 56  
*Hcs* modifier allele, 56  
HDACs (histone deacetylase inhibitors), 7  
Heat shock protein, 143, 144f  
Hematopoietic cancer/tumors  
  ex vivo manipulation of hematopoietic stem cells (HSCs), 204  
  loss-of-function screening in hematopoietic malignancies (protocol), 224–226  
  discussion, 226  
  materials, 224  
  method, 224–226, 225f  
  assessing tumor engraftment efficiency, 225  
  deconvoluting shRNA representation, 225–226  
  reconstituting mice with modified liver stem cells, 225  
  troubleshooting, 226  
  NSG mice with human PDX tumors as models for identification and directed therapy toward tumor-initiating cells (TICS), 259–261, 259t  
  NSG mice with human PDX tumors as models for testing drug efficacy, 257, 257t  
  pathological examination, 277  
  reconstitution of mice with modified HSCs (protocol), 209–214  
  discussion, 212–213  
  materials, 209–210  
  method, 210–212, 210f  
  infection, 211  
  injection, 212  
  isolation of HSCs from bone marrow, 211  
  isolation of HSCs from fetal liver, 210–211  
  recipes, 213–214  
  troubleshooting, 212  
  RNAi use in vivo, 205  
  synergetic transplants with modified chimeric hematopoietic tumors (protocol), 219–223  
  discussion, 222, 222f  
  materials, 219–220  
  method, 220–221  
  recipes, 222–223  
  troubleshooting, 221–222  
  tetracycline-regulated model system, 130t, 133  
Hematopoietic stem cells (HSCs)  
  *Eμ-myc*, 204  
  ex vivo manipulation of, 204  
  reconstitution of mice with modified HSCs (protocol), 209–214  
  discussion, 212–213  
  materials, 209–210  
  method, 210–212, 210f  
  infection, 211  
  injection, 212  
  isolation of HSCs from bone marrow, 211  
  isolation of HSCs from fetal liver, 210–211  
  recipes, 213–214  
  troubleshooting, 212  
  synergetic transplants with modified chimeric hematopoietic tumors (protocol), 219–223  
  discussion, 222, 222f  
  materials, 219–220  
  method, 220–221  
  recipes, 222–223  
  troubleshooting, 221–222  
Hematoxylin and eosin staining of mouse tissue sections (protocol), 300–303  
  discussion, 302  
  materials, 300–301  
  method, 301  
  recipes, 302–303  
  troubleshooting, 301–302  
Hematoxylin solution (Mayer's) (recipe), 303, 307  
Hemocytometer, counting viable cells using, 360, 373  
Hepatoblasts, purification, culture, and retroviral infection of, 216–217  
Hepatocellular carcinoma (HCC), 132, 205.  
  *See also* Liver cancer  
  *Pten* conditional knockout models, 42  
Hepatocyte growth factor (HGF) receptor, 235  
Hepatocyte growth medium (recipe), 218  
HEPES-buffered saline (HBS) precipitation buffer (2 ×)  
  (recipe), 368  
Herpes simplex virus thymidine kinase, 18–19  
HER2-targeted inhibitors, 134  
High-glucose complete medium (recipe), 369  
Histomount solution, 393  
Histone deacetylase inhibitors (HDACs), 7  
Homogenization  
  of spleen, 385, 397  
  of tumor tissue, 386, 398  
Homologous recombination, 4, 90, 93, 98, 99f, 100  
Hormone-binding domain (HBD) fusions, 143–144, 144f, 151  
Housing and husbandry, 462  
H1 promoter, 189  
*Hprt* gene, 5  
*Hras* gene, 57  
HSCs. *See* Hematopoietic stem cells  
Hsp90 inhibitors, 138  
*HSV1-tk*, 316  
<sup>3</sup>H-thymidine uptake, 399–400  
HYDRA (software tool), 492  
4-hydroxytamoxifen (4-OHT), 95, 96, 144, 151–152, 180
- ## I
- ICGC (International Cancer Genome Consortium), 482, 489, 490t–491t, 493, 495  
IF buffer (recipe), 415  
IFP1.4, 313–314  
*IgH* enhancer, 133  
IKMC (International Knockout Mouse Consortium), 44  
IL27 efficacy testing for acute myelogenous leukemia (AML), 258  
*IL2rg<sup>null</sup>* mice, 253, 254, 256  
Imaging, 325–346  
  considerations in designing clinical trials, 459  
  <sup>18</sup>F-FDG-PET/CT imaging of drug-induced metabolic changes in genetically engineered mouse lung cancer models (protocol), 335–338  
  discussion, 337  
  materials, 335–336  
  method, 336–337  
  in vivo using reporter transgenes, 309–320  
  bioluminescence imaging  
    key features, 311–312  
    overview, 310–312, 311f, 313f  
  fluorescence imaging, 312–314, 313f  
  magnetic resonance imaging (MRI), 314–315, 315f  
  overview, 309  
  positron emission tomography (PET), 315, 315f, 316–317  
  practical features of commonly used reporter transgenes, 310t  
  versatility of reporter-transgene-based imaging, 317–320  
    coexpression and reporter tagging strategies, 318–319  
    constitutive expression used to measure tumor burden, 317–318  
  overview of noninvasive imaging, 325–333  
    anesthesia and, 327  
    bioluminescence imaging, 330–331, 330f  
    CT, 327–328  
    experimental workflow, 332–333  
    fluorescence imaging, 331  
    general considerations, 327  
    MRI, 328–330, 329f  
    optical imaging, 330–331  
    PET, 327–328, 328f  
    physiological monitoring and control, 327  
    SPECT, 327–328  
    strengths and limitations of approaches, 326t  
    ultrasound, 331–332

- preclinical magnetic resonance imaging in mouse cancer models (protocol), 339–342
    - discussion, 341–342, 342t
    - materials, 339–340
    - method, 340–341
    - sample protocol, 341b
  - quantitative bioluminescence imaging of mouse tumor models (protocol), 343–346
    - discussion, 345–346
    - materials, 343–344
    - method, 344
    - recipe, 346
    - troubleshooting, 344–345
  - for translational therapeutic studies, 435
  - Imatinib, 134, 206, 261
  - Immune assay, standardization and standard operating procedures for, 486–487
  - Immune cell populations, cell surface markers for, 387t
  - Immune infiltrates, 487–488
  - Immune system analysis, 381–400
    - immunohistochemical assessment
      - of immune cells in mouse tumor tissue (protocol), 390–395
      - discussion, 395
      - materials, 390–391, 391t
      - method, 391–393
      - recipe, 395
      - sample images, 394f
      - troubleshooting, 394
    - immunosurveillance, 381–382
    - multicolor flow cytometric analysis of immune cell subsets in tumor-bearing mice (protocol), 384–389
      - discussion, 387–388
      - materials, 384–385
      - method, 385–387, 387t, 388f
      - FACS analysis, 386–387, 387t, 388t
      - preparation of single-cell suspension from solid tissue or tumor, 386
      - preparation of single-cell suspension from spleen, 385–386
      - troubleshooting, 387
    - myeloid-derived suppressor cell-mediated T-cell suspension assay (protocol), 396–400
      - discussion, 400
      - materials, 396–397
      - method, 397–400
      - isolation of Gr-1<sup>+</sup> cells, 398–399
      - plate setup, 399t
      - preparation of single-cell suspensions from spleens, 397–398
      - preparation of single-cell suspensions from tumors, 398
      - T-cell suspension assay, 399–400, 399t
      - troubleshooting, 400
    - tumor inflammation, 381–382
  - Immune system and immunity
    - characterization of tumor immune environment, 487–488
    - cryopreservation of mouse lymphocytes and immune cells, 485–486
    - immune assay standardization and SOPs, 486–487
  - Immunodeficient mouse models, 253–271
    - athymic *Foxl1<sup>nu</sup>* (nude) mice, 254, 255t
    - C.B17-*Prkdc<sup>scid</sup>* (*scid*) mice, 254–255, 255t
    - NOD.C.B17-*Prkdc<sup>scid</sup>* (NOD-*scid*) mice, 255–256, 255t
    - NOD-*Prkdc<sup>scid</sup>* *IL2rg<sup>null</sup>* (NSG) mice, 254, 255t, 256–264, 257t, 259t, 262f
    - NODShi.Cg-*Prkdc<sup>scid</sup>* *IL2rg<sup>null</sup>* (NOG) mice, 256
    - NSG mice with human PDX tumors as models
      - for identification and directed therapy toward TICS, 259–261, 259t
      - for immunotherapy, 258–259
      - for testing drug efficacy, 256–257
      - hematological tumors, 257, 257t
      - solid tumors, 256–257, 257t
  - overview, 253–254
  - patient-derived xenograft (PDX), 254, 256–263, 257t, 262f
  - PDX programs, 261–263
    - avatar mice, 262–263
    - at Jackson Laboratory, 261–262
  - remaining challenges and future directions in, 263–264
  - subcapsular transplantation of tissue in the kidney (protocol), 268–271
    - discussion, 271
    - materials, 268–269
    - method, 269–270
    - troubleshooting, 270
- Immunoediting, 382
- Immunohistochemistry
  - assessment of immune cells in mouse tumor tissue (protocol), 390–395
    - discussion, 395
    - materials, 390–391, 391t
    - method, 391–393
    - recipe, 395
    - sample images, 394f
    - troubleshooting, 394
  - in epithelial-mesenchymal transition (EMT) tumor, 283f
  - markers used to assess therapy response, 433t
  - staining of mouse tissues using the avidin-biotin complex (ABC) technique (protocol), 304–307
    - discussion, 306–307
    - material, 304–305
    - method, 305–306
    - recipes, 307
    - troubleshooting, 306
- Immunometrics, 487
- Immunomics for biomarker discovery, 481b
- Immunoscore, 487
- Immunosurveillance, 381–382
- IMPC (International Mouse Phenotype Consortium), 44
- Inbred mouse strains. *See also specific strains*
  - Collaborative Cross
    - overview, 73
    - protocol, 81–87
  - genetic effects on cancer genes, 72–73, 72t
  - origin of, 69, 70f
  - protocols
    - controlling genetic background in crosses of mouse models of cancer, 76–80
    - comparing mice homozygous for floxed allele and Cre transgene to sibling controls on a mixed background (example), 78f, 79
    - comparing single-mutant allele to wild types on an inbred strain background (example), 77–79, 78f
- discussion, 79–80
- materials, 76–77
- method, 77–79, 78f
- using collaborative cross to study role of genetic diversity in cancer-related phenotypes, 81–87
- carcinogen/pathogen/cancer-related physiology (example), 82, 83f
- discussion, 84–85
- genetically engineered mouse model (example), 82, 83f, 84
- materials, 81–82
- method, 82–84, 83f
- syngeneic tumor graft model (example), 83f, 84
- variation across strains
  - controlling
    - overview of, 71–72
    - protocol for, 76–80
  - sources of, 70–71
    - insertions and deletions (INDELs), 70
    - mitochondrial genome, 71
    - X chromosome, 71
    - Y chromosome, 71
    - "wild-derived," 69, 70f
- INDELs (insertions and deletions), 70
- Inflammation, tumor, 381–382
- Information management, for translational therapeutic studies, 435
- Infrastructure, for translational therapeutic studies, 434–435
- Inhalational anesthesia
  - for imaging, 327, 336, 337, 340, 344
  - for surgery, 443, 447–448
- InkAa*
  - analysis in germline mouse models of cancer, 30–31
  - deletion of, 204
  - shRNA targeting of, 198
- Inparanoid (software tool), 494
- Insertional mutagenesis. *See* Transposon-based insertional mutagenesis
- Insertions and deletions (INDELs), 70
- Institutional safety office, 499
- Insulinoma model of metastasis, 348–349
- Insulin* promoter, 23, 145, 147, 349
- Internal ribosome entry sequence (IRES), 98, 319
- International Cancer Genome Consortium (ICGC), 482, 489, 490t–491t, 493, 495
- International Knockout Mouse Consortium (IKMC), 44
- International Mouse Phenotype Consortium (IMPC), 44
- Intervention trials, 430
- Intestinal epithelial stem cell medium (recipe), 420
- Intranasal instillation of virus into mice, 120
- Intraperitoneal injection, 432
- Intravenous injection, 432
- Inverted repeats, 173
- InVEx (software), 494
- Involucrin promoter, 146
- IRES (internal ribosome entry sequence), 98, 319
- iRFP, 313–314
- "is\_a" relationships, 469, 470, 471
- Isoflurane
  - for imaging, 337, 340, 344
  - for surgery, 443, 447–448

## Index

### J

- Jackson Laboratory
  - founding of, 2
  - patient-derived xenograft (PDX) program, 261–262
- Jaenisch, Rudolf, 2, 3, 3f, 18

### K

- Keratinocyte 14 (*K14*) promoter, 35, 37
- Keratin promoters, 133
- Kidney, subcapsular transplantation of tissue in (protocol), 268–271
  - discussion, 271
  - materials, 268–269
  - method, 269–270
  - troubleshooting, 270
- KiSS1*, 349
- Kit*, knock-in models of cancer, 90, 92t
- Knock-in mouse models, 89–101
  - conditional models, 93–95
    - maintenance of wild-type gene expression, 95
    - regulating recombination/activation, 95–97
    - removable transcriptional terminal stop elements, 93–95, 94f
  - examples, 92t
  - facilitation of detection, 97–98
  - future of, 98–101
    - design and selection of site-specific nucleases, 100
    - generation of mice, 100–101
    - genome editors, 101
    - improved technologies for generation of mice, 98
    - site-specific engineered nuclease technology, 98–100, 99f
  - knock-in technology described, 90
  - modeling familial cancer using germline KI mice, 90
  - regulating recombination/activation, 95–97
    - inducible recombinase expression, 95
    - overexpression of oncogene, 97
    - reversible gene regulation, 97
    - sequential and/or spatial regulation of multiple alleles, 96–97
    - tissue-specific expression, 96
    - viral delivery of recombinase, 96
  - of somatic human cancer, 90–95
  - stochastic models, 93
  - types of knock-in alleles, 91f
- Köhler illumination, 289
- KPC model of pancreatic ductal adenocarcinoma, 446–447
- Kras*
  - in carcinogen-induced tumors models, 137
  - knock-in models of cancer, 92t, 93, 95–96
  - in lung cancers, 12, 65, 131
    - non-small-cell lung cancer (NSCLC) and, 149
    - in urethane-induced tumors, 137
  - models in pre-/co-/postclinical trials, 458
  - RCAS-*Kras*, 160
  - Sleeping Beauty* mutagenesis and, 179
  - tetracycline-regulated systems and, 128, 135

### L

- Lacy, Elizabeth, 2
- LAP* (liver-activated protein) promoter, in tetracycline-regulated systems, 132

- Laser safety, 500
- Latent mouse model, 93
- Lathrop, Abbie, 1
- LDD (Lhermitte–Duclos disease), 29
- Leder, Philip, 4, 4f, 5
- Lens tumors, 94
- Lentivirus
  - gene delivery, 111–112
  - in vivo delivery of lenti-Cre or adeno-Cre into mice using intranasal instillation (protocol), 119–121
    - materials, 119–120
    - method, 120
    - recipe, 121
    - troubleshooting, 120–121
  - producing and concentrating lenti-Cre for mouse infections (protocol), 116–118
    - materials, 116–117
    - method, 117–118
  - shRNA delivery, 192
- Leukemia. *See also* Hematopoietic cancer
  - acute lymphoblastic leukemia (ALL), 257, 257t
  - acute myelogenous leukemia (AML), 257, 257t, 258, 260
  - acute promyelocytic leukemia (APL), 6–7, 7f, 436, 456, 493–494
  - chronic myelogenous leukemia (CML), 261
  - NSG mice with human PDX tumors as models for identification and directed therapy toward tumor-initiating cells (TICS), 259–261, 259t
  - NSG mice with human PDX tumors as models for testing drug efficacy, 257, 257t
- Leukemia inhibitory factor (LIF), 198
- Ley, Timothy, 6
- Lgr5*<sup>+</sup> adenoma cells, 350
- Lhermitte–Duclos disease (LDD), 29
- Li-Fraumeni syndrome, 90
- Ligand-induced recombination, 145
- Lineage tracing in metastatic models, 350–351
- Little, Clarence Cook, 1–2, 2f
- Liver
  - isolation of HSCs from fetal liver, 210–211
  - reconstitution of mice with modified liver stem cells (protocol), 215–218
    - discussion, 217
    - materials, 215–216
    - method, 216–217
      - generation of genetically defined liver carcinomas, 217
      - purification, culture, and retroviral infection of hepatoblasts, 216–217
      - tumor retransplantation, 217
    - recipes, 218
  - Liver-activated protein (*LAP*) promoter, in tetracycline-regulated systems, 132
- Liver cancer
  - chimeric models to study, 205
  - genetic screens in transplant models, 207
  - induction of liver tumors in mice with *N*-ethyl-*N*-nitrosourea or *N*-nitrosodiethylamine (protocol), 61–62
  - tetracycline-regulated model system, 130t, 132
- Loeb, Leo, 1
- Logic, description, 470

- Loss-of-function screening in hematopoietic malignancies (protocol), 224–226
- Loss of heterozygous (LOH), 44
- loxP* sites, 94, 106–108, 106f, 107t, 113
- Lox-STOP-lox (LSL) cassette, 94–97, 94f
- LRP (lysine-rich protein), 316
- LTR, in RCAS-TVA system, 155–156, 156f
- Luciferase, 330–331, 343
- Luciferin/D-luciferin, 310–312, 311f, 344, 364, 367
  - properties of, 345
  - routes of injection, 345–346
- D-luciferin substrate solution (7.5 mg/mL) (recipe), 346
- Lung cancer
  - circulating cancer markers for, 480
  - coclinical trial, 11–12
  - combinational therapy, 9
  - epidermal growth factor receptor (EGFR) mutations in, 137–138, 452
  - <sup>18</sup>F-FDG-PET/CT imaging of drug-induced metabolic changes in genetically engineered mouse lung cancer models (protocol), 335–338
    - discussion, 337
    - materials, 335–336
    - method, 336–337
  - generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mice (protocol), 450–453
    - discussion, 452, 452f
    - materials, 450–451
    - method, 451
    - recipe, 452–453
    - troubleshooting, 451
  - induction of lung tumors in mice with urethane (protocol), 63–65, 64f
  - in vivo delivery of lenti-Cre or adeno-Cre into mice using intranasal instillation (protocol), 119–121
    - materials, 119–120
    - method, 120
    - recipe, 121
    - troubleshooting, 120–121
  - Kras* mutations, 12, 131, 137, 149
  - tetracycline-regulated model system, 130t, 131–132
- Lung tissue dissociation for metastatic studies (protocol), 358–363
- Lymphocytes
  - cryopreservation of, 485–486
  - standardization and standard operating procedures for immune assays, 486–487
- Lymphoma. *See also* Hematopoietic cancer
  - Burkitt's, 22, 204
  - Eμ-myc* lymphoma model, 3–4, 22, 148, 190, 191, 193, 204, 206
- Lysine-rich protein (LRP), 316

### M

- Magnetic resonance imaging (MRI)
  - angiography, 330
  - arterial spin labeling, 330
  - "desktop" instruments, 329
  - diffusion tensor imaging, 329–330
  - diffusion-weighted imaging (DWI), 329, 341



- dynamic contrast-enhanced MRI (DCE-MRI), 330, 341
  - dynamic susceptibility MRI, 330
  - effects of altering parameters, 342t
  - image quality, 342
  - MR spectroscopy (MRS), 341–342
  - overview, 314–315, 315f, 328–330, 329f
  - perfusion MRI, 330, 341
  - preclinical magnetic resonance imaging in mouse cancer models (protocol), 339–342
    - discussion, 341–342, 342t
    - materials, 339–340
    - method, 340–341
    - sample protocol, 341b
  - reporters, 315–316
  - strengths and limitations of, 326t
  - Magnetic resonance reporters, 315–316
  - Malignancy, pathology of, 281, 281f
  - Mammary cells
    - enrichment of mammary basal and luminal cells for cell-of-origin metastatic studies (protocol), 370–373
      - discussion, 373
      - materials, 370–371
      - method, 371–373, 372f
      - recipes, 373
    - murine stem cell-based retrovirus
      - production for marking primary mouse mammary cells for metastasis studies (protocol), 364–369
        - discussion, 368
        - materials, 364–365
        - method, 365–368
        - recipes, 368–369
        - troubleshooting, 368
    - organotypic culture of untransformed and tumorigenic primary mammary epithelial cells (protocol), 412–416
      - discussion, 414
      - materials, 412–413
      - method, 413–414
      - recipes, 415
      - troubleshooting, 414
    - tissue dissociation for metastatic studies (protocol), 358–363
      - counting cells, 360
      - discussion, 361
      - dissociation of tissue, 359–360
      - mammary cell culture and viral transduction, 360
      - materials, 358–359
      - method, 359–360
      - recipes, 362
      - troubleshooting, 361
  - Mammary fat pad
    - as an orthotopic site for studying breast cancer, 229–230
    - cleared mammary fat pad transplantation assay for mammary epithelial organogenesis (protocol), 247–251
    - cleared MFP transplantation, 249–250, 250f
    - dissociation of mouse mammary tissue, 248–249, 249f
    - materials, 247–248
    - method, 248–250, 249f, 250f
    - recipes, 250–251
  - Mammary gland cancer. *See* Breast cancer
  - Marking primary mouse mammary cells
    - for metastasis studies, murine stem cell-based retrovirus production for (protocol), 364–369
      - discussion, 368
      - materials, 364–365
      - method, 365–368
      - recipes, 368–369
      - troubleshooting, 368
  - MART-1 melanoma antigen, 258
  - "Matched pairs" of tumors, 203
  - Material safety data sheets (MSDSs), 499
  - Material transfer agreement (MTA), 12, 463
  - Matrix metalloproteinase 3 (Mmp3), 230
  - Matrix metalloproteinase 9 (Mmp9), 230
  - Maximum tolerated dose (MTD), 431–432
  - McClintock, Barbara, 173
  - MDM2 (mouse double minute 2 homolog), 148
  - MDMX, 148
  - Mdr1a and Mdr1b (drug transporters), 436
  - Medical Pathological Waste (MPW), 501
  - Medulloblastoma, modeling using *Sleeping Beauty* transposon-based insertional mutagenesis, 179
  - Melanomas, *BRAF and*, 458
  - Metabolic profiling, for biomarker discovery, 480–481, 481b
  - Metadata, 468
  - Metastasis, 347–379
    - genetically modified mouse models of metastatic disease, 348
    - pathology of, 281f, 282–283
    - protocols for studying, 358–379
      - enrichment of mammary basal and luminal cells for cell-of-origin metastatic studies, 370–373
        - discussion, 373
        - materials, 370–371
        - method, 371–373, 372f
        - recipes, 373
      - isolating epithelial and epithelial-to-mesenchymal transition populations from primary tumors by FACS, 374–376
        - discussion, 376
        - materials, 374–375
        - method, 375–376
    - murine stem cell-based retrovirus
      - production for marking primary mouse mammary cells for metastasis studies, 364–369
        - discussion, 368
        - materials, 364–365
        - method, 365–368
        - recipes, 368–369
        - troubleshooting, 368
    - orthotopic injection of pancreatic cancer cells, 377–379
      - discussion, 379
      - materials, 377–378
      - method, 378–379
    - tissue dissociation for metastatic studies, 358–363
      - counting cells, 360
      - discussion, 361
      - dissociation of tissue, 359–360
      - mammary cell culture and viral transduction, 360
      - materials, 358–359
      - method, 359–360
  - recipes, 362
  - troubleshooting, 361
- Methanol fixative, 392
- 3-methylcholanthrene, 52
- Microinjection
  - history of, 18
  - pronuclear of DNA, 18, 21
- MicroPET, 316
- Microplate reader, analysis of retrovirus-transduced cells with, 367
- microRNAs (miRNAs), 188
  - biogenesis and introduction of exogenous RNAi triggers, 189f
  - as blood based cancer markers, 482
  - RNA Pol II transcription of, 190
- Microscopy
  - analysis of retrovirus-transduced cells
    - with fluorescence microscopy, 367
  - key features of focal lesions, 279t
  - microscope slide examination, algorithm for, 277f
  - pathologic processes of focal lesions, 280f
- Microwave safety, 500
- Middle T-antigen of murine polyomavirus (PyVMT), 21
- MIG vectors, 364, 366, 368
- Minos* transposon-based insertional mutagenesis, 179–180
- Mintz, Beatrice, 2, 3, 3f, 18
- MiR30-based shRNA, 194
- miRNAs. *See* microRNAs (miRNAs)
- MiR30 shRNA, 189f, 190–191, 193
- Mitochondrial genome, polymorphisms in, 71
- MIT vectors, 352, 364, 366, 368
- MMHCC. *See* Mouse Models of Human Cancer Consortium
- Mmp3 (matrix metalloproteinase 3), 230
- Mmp9 (matrix metalloproteinase 9), 230
- MMTV. *See* Mouse mammary tumor virus
- MMTV-Cre transgene, 42
- MMTV-H-Ras, 20
- MMTV-LTR, 20–21
- MMTV-Myc, 4, 20–21
- MMTV-*Neu* breast cancer model, 349, 351
- MMTV-PyMT mammary tumor model, 349, 351
- MMTV-Ras, 20–21
- MMTV-Wnt1, 20
- M-MuLV (Moloney leukemia virus), 2
- Molecular profiling, blood and plasma collection for, 483
- Moloney leukemia virus (M-MuLV), 2
- Mom* allele, 56
- Monte Carlo method, for identification of transposon insertion sites, 177–178

## Index

- Mouse double minute 2 homolog (MDM2), 148  
Mouse Hospital  
  housing and husbandry, 462  
  infrastructure for, 463f  
  pharmacy for, 462–463, 463b  
Mouse mammary tumor virus (MMTV), 20–21  
  long terminal repeat in tetracycline-regulated model system, 129, 131t  
  MMTV-Cre transgene, 42  
  MMTV-Myc mice, 4  
  MMTV-Neu breast cancer model, 349, 351  
  MMTV-PyMT mammary tumor model, 349, 351  
Mouse Models of Human Cancer Consortium (MMHCC), 287, 462, 467, 468, 487, 488  
Mouse Pathology Ontology (MPATH), 470  
Mouse strains. *See* Inbred mouse strains  
MPATH (Mouse Pathology Ontology), 470  
MPW (Medical Pathological Waste), 501  
MRI. *See* Magnetic resonance imaging  
MR spectroscopy (MRS), 341–342  
MSCV promoter  
  *piggyBac* transposons and, 180  
  *Sleeping Beauty* transposons and, 175t, 176  
MSDSs (material safety data sheets), 499  
MTA (material transfer agreement), 12, 463  
MTD (maximum tolerated dose), 431–432  
mTOR, 206  
mTORC1 complex, 428  
*Mtl* promoter, 3  
Multicolor flow cytometric analysis of immune cell subsets in tumor-bearing mice (protocol), 384–389  
  discussion, 387–388  
  materials, 384–385  
  method, 385–387, 387t, 388f  
  FACS analysis, 386–387, 387t, 388t  
  preparation of single-cell suspension from solid tissue or tumor, 386  
  preparation of single-cell suspension from spleen, 385–386  
  troubleshooting, 387  
Mutagenesis. *See* Transposon-based insertional mutagenesis  
*Mx1-Cre* mice, 111  
*Myc*  
  cooperation between oncogenic signals, 136  
  early studies on, 3–4  
  *Eμ-myc* lymphoma model, 3–4, 148, 204, 206  
  in hepatocellular tumors, 132  
  MMTV-Myc mice, 4  
  Myc-induced lymphomagenesis, 204  
  oncogene addiction and cancer recurrence, 134–136  
MycER<sup>T2</sup>, 147  
MycER<sup>TAM</sup>, 147  
Myeloid-derived suppressor cell-mediated T-cell suspension assay (protocol), 396–400  
  discussion, 400  
  materials, 396–397  
  method, 397–400  
  isolation of Gr-1<sup>+</sup> cells, 398–399  
  plate setup, 399t  
  preparation of single-cell suspensions from spleens, 397–398  
  preparation of single-cell suspensions from tumors, 398  
  T-cell suspension assay, 399–400, 399t  
  troubleshooting, 400  
**N**  
National Cancer Institute (NCI)  
  Carcinogenesis Bioassay Program, 53  
  Mouse Models of Human Cancer Consortium (MMHCC), 287, 462, 467, 468, 487, 488  
National Institute of Environmental Health and Human Services, 503  
National Toxicology Program (NTP), 53  
Natural killer (NK) cells, 254, 255, 258  
Necropsy  
  limited mouse necropsy (protocol), 293–296  
  discussion, 295  
  materials, 293–294  
  method, 294–295  
  reference guides, 285  
Nestin gene promoter, 159–160  
*N*-ethyl-*N*-nitrosourea (ENU)  
  induction of liver tumors in mice with *N*-ethyl-*N*-nitrosourea or *N*-nitrosodiethylamine (protocol), 61–62  
  use to identify lung cancer susceptibility loci, 56  
Neurofibromatosis, 30  
Neutralized collagen (recipe), 246  
Next-generation sequencing (NGS) technologies, 489, 493  
NHEJ (nonhomologous end joining), 98, 100–101  
*Nfl/2*, analysis in germline mouse models of cancer, 30  
NIS (sodium iodide symporter), 316  
Nitrosoamines, as carcinogens, 53  
NK (natural killer) cells, 254, 255, 258  
*Nm22*, 349  
*NMR and Its Applications to Living Systems* (Gadian), 314  
*N*-nitroso compounds, as carcinogens, 53  
*N*-nitrosodiethylamine (DEN)  
  early animal studies on, 53  
  induction of liver tumors in mice with *N*-ethyl-*N*-nitrosourea or *N*-nitrosodiethylamine (protocol), 61–62  
*N*-nitrosodimethylamine (DMN), early animal studies on, 53  
NNK, 65  
NOD-*Prkdc*<sup>scid</sup> *IL2rg*<sup>null</sup> mice, 254, 255t, 256–264, 257t, 259t, 262f.  
  *See also* NSG mice  
NOD-*scid* *IL2rg*<sup>null</sup> strain, 253, 254.  
  *See also* NSG mice  
NODShi.Cg-*Prkdc*<sup>scid</sup> *IL2rg*<sup>null</sup> (NOG) mice, 256  
Nongermine GEMMs  
  accelerating mouse model production using, 196, 197f  
  generation of multiallelic via ES cell rederivation, 197–198  
Nonhomologous end joining (NHEJ), 98, 100–101  
Non-oncogene addiction, 284  
Non-small-cell lung cancer (NSCLC)  
  p53 and, 148–149  
  patient-derived xenograft (PDX) in NSG mice, 256  
Nowell, Peter, 183  
Nowell's clonal evolution model of cancer development, 55  
NSCLC. *See* Non-small-cell lung cancer  
NSG mice, 253–264  
  development of, 254, 255t, 256  
  with human PDX tumors as models for identification and directed therapy toward TICS, 259–261, 259t  
  for immunotherapy, 258–259  
  for testing drug efficacy, 256–257  
  hematological tumors, 257, 257t  
  solid tumors, 256–257, 257t  
NTP (National Toxicology Program), 53  
Nucleic acids, assays of tumor-derived, 482  
Nucleic acids-based profiling, for biomarker discovery, 481b  
Nude mice, 254, 255t  
**O**  
Occupational Safety and Health Administration (OSHA), 499  
Oncogene  
  ER-fused, 146–147  
  overexpression of, 97  
Oncogene addiction  
  cancer recurrence, 134–136  
  pathology, 284  
Oncogenic signals, cooperation between, 136  
Oncomouse, 3–4  
Oncomouse patent, 5–6  
Ontogeny of disease, 274f  
Optical imaging, 330–331  
Optical window, 314f  
Optimal cutting temperature (OCT) medium, 390  
Oral gavage, 432  
Organ transplantation models, 203–226  
Orthotopic injection of pancreatic cancer cells (protocol), 377–379  
  discussion, 379  
  materials, 377–378  
  method, 378–379  
Orthotopic transplantation, 228–229  
OSHA (Occupational Safety and Health Administration), 499  
12-*O*-tetradecanoylphorbol-13-acetate (TPA), 54, 55  
Ovarian cancer, CA125 marker for, 480  
Overexpression of an oncogene, 97  
**P**  
p27  
  analysis in germline mouse models of cancer, 31  
  colon cancer and, 67  
  combining chemical carcinogenesis and genetically engineered models of cancer, 55–56  
  lung cancer and, 65  
p53  
  analysis in germline mouse models of cancer, 28–29  
  carcinogen bioassay and, 57  
  combining chemical carcinogenesis and genetically engineered models of cancer, 55–56  
  conditional knockout mouse models, 40  
  cooperation between oncogenic signals, 136  
  DMBA/TPA skin cancer protocol and, 57  
  knockdown in lymphoma model, 190  
  LFS (loss-of-function) mouse models, 40  
  p53ER<sup>TAM</sup>, 147–149, 148f  
  RNAi-mediated knockdown, 231

- shRNA, 193
  - p107*, 41
  - PAHs (polycyclic aromatic hydrocarbons), 52, 54
  - Palmiter, Richard, 3, 5, 7, 18, 19, 22
  - Pancreas
    - culturing primary mouse pancreatic ductal cells (protocol), 404–407
      - materials, 404–405
      - method, 405–406
        - culturing and passaging cells, 406
        - single-cell suspension preparation, 405
      - recipes, 406–407
      - troubleshooting, 406
    - immunohistochemical images of tissue, 394f
    - pancreatic epithelial cells
      - creating primary cell lines from lineage-labeled mouse-models (protocol), 408–411
        - discussion, 410–411
        - materials, 408–409
        - method, 409–410
        - recipes, 411
        - troubleshooting, 410
      - isolating epithelial and epithelial-to-mesenchymal transition populations from primary tumors by FACS (protocol), 374–376
        - discussion, 376
        - materials, 374–375
        - method, 375–376
      - tissue-specific oncogene expression in, 22–23
  - Pancreatic cancer
    - CA19-9 marker for, 480
    - combinational therapy, 9
    - microRNAs (miRNAs) as blood based cancer markers, 482
    - modeling using *Sleeping Beauty* transposon-based insertional mutagenesis, 179
    - tetracycline-regulated model system, 131t, 132
    - ultrasound imaging for evaluating tumors, 446
  - Pancreatic ductal adenocarcinoma (PDA), 132.
    - See also Pancreatic cancer
    - acquisition of mouse tumor biopsies through abdominal laparotomy (protocol), 440–449
    - knock-in models of, 96
    - KPC model of, 446–447
    - orthotopic injection of pancreatic cancer cells (protocol), 377–379
      - discussion, 379
      - materials, 377–378
      - method, 378–379
    - resistance to therapy, 437
    - SMAD4* gene and, 43
    - ultrasound imaging of, 443f
  - Pancreatic ductal epithelial cell medium (recipe), 411
  - Pandolfi, Pier Paolo, 6, 10, 11
  - PANTHER (software tool), 494
  - Paraformaldehyde fixative, 123, 298
  - p19ARF*, 30–31, 149
  - Patents, 5–6
  - Pathologist, choosing, 286–287
  - Pathology, 273–307
    - defined/described, 274–275
    - general disease processes, 275t
    - handling experimental data, 287–290
      - data organization and integration, 287–288
      - image presentation, 289
    - understanding nomenclature, 288–289
    - whole-slide imaging (WSI), 289–290, 290t
  - online training programs, 295
  - pathobiology of cancer in genetically engineered mice, 274–285
    - critical background information, 276
    - general disease processes, 275t
    - gross specimen logic tree, 276f
    - gross tissue examination, 279
    - malignancy, 281, 281f
    - metastasis, 281f, 282–283
    - microscopy
      - microscope slide examination, algorithm for, 277f
      - misinterpretations of pathology, 278f
      - tissue examination, 279
    - natural history of cancer, 279–282
    - neoplastic variation, heterogeneity, and reproducibility, 283–285
    - ontogeny of disease, 274f
    - pathology of cancer, 275–278
    - pre-cancer identification, 279–282, 281f
  - postage stamp, 289
  - protocols
    - limited mouse necropsy, 293–296
      - discussion, 295
      - materials, 293–294
      - method, 294–295
    - manual hematoxylin and eosin staining of mouse tissue sections, 300–303
      - discussion, 302
      - materials, 300–301
      - method, 301
      - recipes, 302–303
      - troubleshooting, 301–302
    - manual immunohistochemistry staining of mouse tissues using the avidin-biotin complex (ABC) technique, 304–307
      - discussion, 306–307
      - material, 304–305
      - method, 305–306
      - recipes, 307
      - troubleshooting, 306
    - mouse tissue fixation, 297–299
      - data for common fixatives, 298t
      - discussion, 298–299
      - fixative choice, 298–299, 298t
      - materials, 297
      - method, 297–298
      - timing and duration of fixation, 299
  - sharing scientific data, 467–478
    - caELMIR example, 467, 468, 470–477
      - Experiment, 471, 472f, 473, 473f
      - pathology, 473
      - slide report, 473, 476f
      - Specimen, 473, 474f, 475f
      - spreadsheet report, 473, 477f
      - Study, 471, 471f, 472f
    - controlled vocabulary, 469–470
    - structured reports, 468–469
  - technical preparation for study of genetically engineered mouse, 285–287, 286f
    - fixation, 285–286
    - handling tissues after fixation, 286
    - interpretation and choosing a pathologist, 286–287
    - necropsy, 285
    - standards, 285
    - study hierarchy, 286f
- Patient-derived xenograft (PDX), 254, 256–263, 257t, 262f
  - engraftment and expansion of, 262f
  - GEMMs as distinct from, 457
  - NSG mice with human PDX tumors as models for identification and directed therapy toward TICs, 259–261, 259t
  - for immunotherapy, 258–259
  - for testing drug efficacy, 256–257
    - hematological tumors, 257, 257t
    - solid tumors, 256–257, 257t
  - PDX programs, 261–263
    - avatar mice, 262–263
    - at Jackson Laboratory, 261–262
    - subcapsular transplantation of tissue in the kidney (protocol), 268–271
      - discussion, 271
      - materials, 268–269
      - method, 269–270
      - troubleshooting, 270
- P1 bacteriophage, 106
- PBS (10×, pH 7.4) (recipe), 362, 373
- PBS with Ca<sup>2+</sup> and Mg<sup>2+</sup> (D-PBS) (recipe), 362
- PCR amplification and sequencing of transposon insertion sites, 176–177, 177f
- PDC full medium (recipe), 407
- PDX. See Patient-derived xenograft
- Pdx1* promoter, 96
- PEG promoter, 318
- Perfusion MRI, 330, 341
- p53ER<sup>TAM</sup>*, 147–149, 148f
- PET. See Positron emission tomography
- Pgk* promoter, 94f, 95
- Pharmacodynamics and pharmacokinetic measurements
  - considerations in trial design, 459
  - in therapeutic trials/studies, 433–434
- Pharmacy, for Mouse Hospital, 462–463, 463b
- Phenotypic end point study, 429
- Phoenix packaging cells, 216
- Phosphatase and tensin homolog. See *Pten*
- Phosphate-buffered saline (PBS) (recipe), 213, 223, 415, 425
- Physiological monitoring and control during imaging, 327
- PiggyBac*
  - PB\_SMART transposon constructs, 181
  - transposon-based insertional mutagenesis, 180–181
- PI3K, 9, 41
- PIK3CA*, knock-in models of cancer, 92t
- Pim1-3*, 206
- PIN (prostate intraepithelial neoplasia) lesions, 231, 233f, 235
- PLZF-RARα* mice, 6–7
- PML-RARα, 6, 436
- Poisson regression insertion model (PRIM), for identification of transposon insertion sites, 178
- Pol II promoters, 190, 191, 193
- Polybrene, 211, 221
- Polybrene (recipe), 213, 218, 223
- Polycyclic aromatic hydrocarbons (PAHs), 52, 54
- Polyomavirus middle T (PyMT) oncogene, 230
- PolyPhen-2 (software tool), 494
- Polysemy, 469
- Poly(A) sequences, 94–95
- Ponasterone A, 149
- Positron emission tomography (PET), 315, 315f, 316–317

## Index

- Positron emission tomography (PET)  
(*Continued*)  
  <sup>18</sup>F-FDG-PET/CT imaging of drug-induced metabolic changes in genetically engineered mouse lung cancer models (protocol), 335–338  
  discussion, 337  
  materials, 335–336  
  method, 336–337  
  overview, 327–328, 328f  
  strengths and limitations of, 326t
- Postclinical trials, 456–460, 456b
- Pott, Percival, 52
- p48* promoter, 132
- Precancer identification, 279–282, 281f
- Preclinical drug testing/trials, 7–9, 456–460, 456b
- Prevention trials, 429–430
- PRIM (Poisson regression insertion model), for identification of transposon insertion sites, 178
- Primary growth medium (recipe), 251
- Probasib-Cre (Pb-Cre), 44
- Proliferation rate, immunohistochemical markers of, 433t
- Promoters. *See also specific promoters*  
  hypermethylation of CpG islands in, 482  
  pancreas specific, 22–23  
  in RCAS-TVA system, 156  
  tetracycline-dependent, 125  
  tissue-specific, 22  
  in tissue-specific Cre-expressing mouse lines, 96, 110f, 110t
- Pronuclear microinjection of DNA, 18, 21
- Prostate  
  dissociated prostate regeneration under the renal capsule (protocol), 243–246  
  dissociation of mouse prostate tissues, 244  
  engraftment of prostate cell recombinants into subrenal capsules, 245  
  materials, 243–244  
  method, 244–245  
  preparation of prostate cell recombinants in collagen plugs, 245  
  recipes, 246  
  troubleshooting, 245  
  graft appearance, 232f–233f  
  preparation of urogenital sinus mesenchymal cells for prostate tissue recombination models (protocol), 240–242  
  materials, 240–241  
  method, 241  
  recipe, 242  
  prostate intraepithelial neoplasia (PIN) lesions, 231, 233f, 235
- Prostate cancer  
  androgen deprivation therapy (ADT), 11  
  castration-resistant (CRPC), 11, 482  
  combinational therapy, 9  
  drug resistance, 11  
  microRNAs (miRNAs) as blood based cancer markers, 482  
  PSA (prostate specific antigen) as marker, 480  
  *SMAD4* conditional knockout models, 44  
  *TRAMP* metastatic prostate cancer model, 351
- Prostate intraepithelial neoplasia (PIN) lesions, 231, 233f, 235
- Prostate specific antigen (PSA), 44, 480
- Proteomics for biomarker discovery, 481b
- PSA (prostate specific antigen), 44, 480
- Pseudopathology, 287
- Ptch*, *Sleeping Beauty* mutagenesis and, 179
- Pten*, 24, 137, 458  
  analysis in germline mouse models of cancer, 29–30  
  conditional knockout mouse models, 41–42  
  models in pre-/co-/postclinical trials, 458  
  RNAi-mediated knockdown, 231  
  *SMAD4* gene and, 43–44
- ## R
- Radiance, 346
- Radiation  
  safety procedures, 502  
  waste disposal, 501, 502
- Rapamycin, 206, 428
- RAR $\alpha$*  gene, 6
- Ras  
  carcinogen bioassay and, 57  
  in carcinogen-induced tumors models, 137  
  cooperation between oncogenic signals, 136  
  DMBA/TPA skin cancer protocol and, 57  
  non-small-cell lung cancer (NSCLC) and, 149
- Rat insulin-II promoter, 23
- Rat Insulin Promoter (*RIP*), 145
- Rb*  
  analysis in germline mouse models of cancer, 29  
  conditional mutant mouse models, 40–41  
  cooperation between oncogenic signals, 136
- RBC lysis buffer for tissue dissociation (recipe), 362
- RCAN virus, 156, 159
- RCAS (replication-competent avian-leukosis virus), 155–171  
  generation of high-titer RCAS virus from DF1 chicken fibroblasts (protocol), 163–168  
  discussion, 167–168  
  materials, 163–164  
  method, 164–166  
  concentration of the virus, 166  
  confirmation of RCAS expression, 165  
  culture of DF1 chicken fibroblasts, 164  
  titration of DF1 viral supernatant, 165–166, 165t, 166t  
  transfection of DF1 chicken fibroblasts, 164–165  
  troubleshooting, 166–167  
  in vivo delivery of RCAS to mice (protocol), 169–171  
  discussion, 170–171  
  materials, 169–170  
  method, 170  
  overview, 155–157  
  RCAS-TVA, 155–160, 156f, 158t  
  advantages, 157–159  
  models using, 158t, 159–160  
  schematic, 156f  
  shortcomings of, 159
- RCAS-Kras, 160
- RCAS-TVA system, 155–160, 156f, 158t  
  advantages, 157–159  
  models using, 158t, 159–160  
  schematic, 156f  
  shortcomings of, 159  
  shRNA delivery, 192  
  tetracycline-regulated systems and, 128
- RCOS virus, 156
- ## Recipes
- Avertin (20 mg/mL), 121
- B-cell freezing medium, 213
- B-cell medium, 213, 222
- BFS growth medium, 242, 246
- BSA coating solution, 250
- collagenase solution, 251
- collagen solution, 406
- complete medium for metastatic studies, 362, 373
- digestion buffer for mammary glands, 415
- digestion solution for tissue dissociation, 362
- eosin Y solutions, 302
- erlotinib, 452–453
- formaldehyde (3%), 395
- G solution, 407
- hematoxylin solution (Mayer's), 303, 307
- hepatocyte growth medium, 218
- HEPES-buffered saline (HBS) precipitation buffer (2 $\times$ ), 368
- high-glucose complete medium, 369
- IF buffer, 415
- intestinal epithelial stem cell medium, 420
- D-luciferin substrate solution (7.5 mg/mL), 346
- neutralized collagen, 246
- pancreatic ductal epithelial cell medium, 411
- PBS (10 $\times$ , pH 7.4), 362, 373
- PBS with Ca<sup>2+</sup> and Mg<sup>2+</sup> (D-PBS), 362
- PDC full medium, 407
- phosphate-buffered saline (PBS), 213, 223, 415, 425
- polybrene, 213, 218, 223
- primary growth medium, 251
- RBC lysis buffer for tissue dissociation, 362
- red blood cell lysis solution, 223
- soaking buffer for mouse intestine, 420
- solution A for organotypic culture, 425
- solution B for organotypic culture, 425
- solution C for organotypic culture, 425
- solution D for organotypic culture, 426
- solution E for organotypic culture, 426
- stem cell supplement (5 $\times$ ), 213
- trypsin-EDTA, 407, 411
- trypsin-EDTA in PBS, 415
- WEHI conditioned medium, 214
- X-gal rinse buffer for Cre expression, 124
- X-gal solution, 124
- Recombinase-mediated cassette exchange (RMCE), rapid site-specific transgene insertion using, 193–195, 195f
- Recombinases. *See Site-specific recombinases; specific recombinases*
- Recombination-activating genes (*Rag1<sup>null</sup>* and *Rag2<sup>null</sup>*), 253–256
- Red blood cell lysis solution (recipe), 223
- Red blood cells, removal from cell suspensions, 385, 397
- Renal capsule, dissociated prostate regeneration under (protocol), 243–246  
  dissociation of mouse prostate tissues, 244  
  engraftment of prostate cell recombinants into subrenal capsules, 245  
  materials, 243–244  
  method, 244–245  
  preparation of prostate cell recombinants in collagen plugs, 245  
  recipes, 246  
  troubleshooting, 245

- Reporter transgenes  
conditional, 98  
defined, 310  
imaging mouse cancer models in vivo using, 309–320  
bioluminescence imaging  
key features, 311–312  
overview, 310–312, 311f, 313f  
fluorescence imaging, 312–314, 313f  
magnetic resonance imaging (MRI), 314–315, 315f  
overview, 309  
positron emission tomography (PET), 315, 315f, 316–317  
practical features of commonly used reporter transgenes, 310t  
versatility of reporter-transgene-based imaging, 317–320  
coexpression and reporter tagging strategies, 318–319  
constitutive expression used to measure tumor burden, 317–318  
practical features of commonly used reporter transgenes for imaging cancer models in vivo, 310t  
validation of Cre activity, 112  
whole-mount X-gal staining of mouse tissues (protocol), 122–124  
materials, 122–123  
method, 123  
recipes, 124  
troubleshooting, 123
- Research Validated Best Practice, 462, 466
- Resistance to cancer therapy  
generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mice (protocol), 450–453  
discussion, 452, 452f  
materials, 450–451  
method, 451  
recipe, 452–453  
troubleshooting, 451  
use of GEMMs to study, 8, 436
- Retinoic acid, 6–7, 8
- Retinoid X receptor (RXR), 149
- Retrovirus, murine stem cell-based production for marking primary mouse mammary cells for metastasis studies (protocol), 364–369
- Reverse tetracycline transactivator (rtTA), 126f, 127–129, 128f, 131, 138, 352, 364
- Reverse transcriptase PCR (RT-PCR), for cancer biomarker discovery, 483
- Reversible gene regulation, 97
- Reversible switch, estrogen receptor (ER) regulatable system as, 143–153
- RGB imaging, 318
- RIP (Rat Insulin Promoter), 145
- RIP-Cre-ER<sup>TAM</sup>, 145
- RIP7 insulin promoter, 132
- RIP-Tag, 23, 349, 458
- RIP1-Tag2 mouse line, 23
- RISC (RNA-induced silencing complex), 188
- Rituximab, 257
- RMCE (recombinase-mediated cassette exchange), rapid site-specific transgene insertion using, 193–195, 195f
- RNAi (RNA interference)  
direct introduction of RNAi vectors in vivo, 192–193  
in germline GEMMs, 193  
modeling cancer in vivo using transplant-based GEMMs and RNAi, 190–192  
reversible regulation of gene expression in vivo, 188  
systems for mammalian cells, 188–198, 189f  
use in loss-of-function hematopoietic tumor screening, 205  
RNA-induced silencing complex (RISC), 188  
RNA Pol III promoters, 189, 190, 193  
RNA Pol II promoters, 190, 191, 193  
RNA polymerase II, 188, 190  
RNA sequencing, 492  
Rosa26 locus  
Flp/FRT homing cassettes, 194  
knock-in models and, 97  
promoter, 147  
*Sleeping Beauty* transposons and, 174, 175t, 176, 181, 182f  
TVA expression regulation by, 160  
ROSA26R reporter mouse, 146  
Rosen, Jeff, 350  
Routes of drug delivery, in therapeutic trials/studies, 432  
*rox* site, 107t, 108  
R26R-confetti, 318  
rtTA (reverse tetracycline transactivator), 126f, 127–129, 128f, 131, 138, 352, 364  
Ruddle, Frank H., 2
- S**
- Safety, 499–504  
biological safety procedures, 502–503  
general cautions, 499–501  
institutional safety office, 499  
material safety data sheets (MSDSs), 499  
properties of common hazardous chemicals, 503–504  
radioactive safety procedures, 502  
waste disposal, 501  
SAMtools (software), 492  
*Sc* (colon cancer susceptibility allele), 56  
*scid* (severe combined immunodeficiency) mice, 253–255, 255t  
Scientifically validated data elements (SVDEs), 468–469, 478  
Secreted phosphoprotein 1 (SPP1), 44  
Selumetinib, 9, 11–12  
SENCAR mouse strain, 56  
Sequencing for cancer genome analysis  
DNA sequencing, 492  
emerging technologies, 493  
experimental design, 495–496, 495f  
RNA sequencing, 492  
sequencing to find DNA-protein interactions, 493  
single-cell sequencing, 493  
Severe combined immunodeficiency (*scid*) mice, 253–255, 255t  
Sevofluorane, 336, 337  
Sharing scientific data, 467–478  
caELMIR example, 467, 468, 470–477  
Experiment, 471, 472f, 473, 473f  
pathology, 473  
slide report, 473, 476f  
Specimen, 473, 474f, 475f  
spreadsheet report, 473, 477f  
Study, 471, 471f, 472f  
controlled vocabulary, 469–470  
infrastructure considerations for curation of data, 465b  
structured reports, 468–469  
Short hairpin RNAs (shRNAs), 188–193  
coexpressed with reporter transgenes, 319  
Dicer-mediated cleavage, 188  
direct introduction of RNAi vectors in vivo, 192–193  
epigenetic silencing, 191  
functional identification of effective, 191  
genetic screens in transplant models, 207  
genome-wide library, 190  
loss-of-function screening in hematopoietic malignancies (protocol), 224–226, 225f  
reconstitution of mice with modified liver stem cells (protocol), 215–218  
stem loop, 191, 193  
stem-loop, 189–190  
structure of, 189  
toxicity of high expression, 191  
shRNAs. *See* Short hairpin RNAs  
SIFT (software tool), 494  
Simian virus 40 (SV40), 3, 18–19, 458  
Single-cell DNA and RNA sequencing, 493  
Single-photon emission CT (SPECT) imaging, 326t, 327–328  
siRNA. *See* Small interfering RNA  
*Sirpa* gene, 255  
Site-specific nucleases, 98–100, 99f  
design and selection of, 100  
Site-specific recombinases, 106–108  
acute regulation of Cre activity, 111  
dual recombinase technology, 112–113  
in knock-in models of cancer, 93–95  
transgenic expression of Cre, 108, 109f, 110f, 110t  
validation of Cre activity, 112  
viral delivery of Cre, 111–112  
Skin cancer, tetracycline-regulated model system for, 130t, 132–133  
*Sleeping Beauty*  
local hopping, 174  
shRNA delivery and, 192–193  
transposon and transposase alleles, 175t  
transposon-based insertional mutagenesis applications of, 176  
hallmarks of *Sleeping Beauty*-driven tumors, 181  
to identify genetic determinants of drug resistance in cancer, 183  
induction of mutagenesis, 178  
modeling solid tumors using, 178–179  
overview, 174–176  
refinements of system, 181–183, 182f  
*SMAD4* conditional knockout mouse models, 43–44  
Small interfering RNA (siRNA)  
Dicer generation of, 188  
synthetic, 188–190  
Small intestinal crypts, culturing adult stem cells from (protocol), 417–421  
discussion, 419–420  
materials, 417–418  
method, 418–419  
culture of isolated crypts, 418–419  
dissociation and culture of single cells, 419  
isolation of crypts, 418  
recipes, 420  
Smithies, Oliver, 5, 33  
Snail, 135, 376

## Index

- Soaking buffer for mouse intestine (recipe), 420  
Society of Toxicological Pathology, 289  
Sodium iodide symporter (NIS), 316  
Solid tumors  
  identification of tumor-initiating cells (TICS), 259t, 260  
  isolation of Gr-1<sup>+</sup> cells, 398–399  
  modeling using *Sleeping Beauty* transposon-based insertional mutagenesis, 178–179  
  NSG mice with human PDX tumors as models for testing drug efficacy, 256–257, 257t  
  preparation of single-cell suspension from, 386, 398  
Solution A for organotypic culture (recipe), 425  
Solution B for organotypic culture (recipe), 425  
Solution C for organotypic culture (recipe), 425  
Solution D for organotypic culture (recipe), 426  
Solution E for organotypic culture (recipe), 426  
Solvents, safe handling of, 500, 503  
SomaticSniper algorithm, 492  
Somatostatin receptor, 316–317  
Soybean trypsin inhibitor, 406  
SPECT (single-photon emission CT) imaging, 326t, 327–328  
Spectral unmixing, 313  
Spectrin-β2, 482  
Spleen  
  immunohistochemical images, 394f  
  isolation of Gr-1<sup>+</sup> cells, 398–399  
  preparation of single-cell suspensions from, 385–386, 397–398  
Splice acceptor, 94f, 95  
Splinkerette PCR, 176, 177, 177f  
SPP1 (secreted phosphoprotein 1), 44  
*Sprouty2*, 137  
Squamous cell carcinoma, metastatic, 350  
Standard operating procedures (SOPs), for clinical trial infrastructure, 462, 464, 465  
STAR algorithm, 492  
Stem cell-based retrovirus production for marking primary mouse mammary cells for metastasis studies (protocol), 364–369  
  discussion, 368  
  materials, 364–365  
  method, 365–368  
  analysis of transduced cells in flow cytometer, 367  
  analysis of transduced cells with bioluminescence imaging, 367  
  analysis of transduced cells with fluorescence microscopy, 367  
  analysis of transduced cells with microplate reader, 367  
  preparation of viral particles, 365–366  
  titer calculation, 367–368  
  titration of viral particles, 366–367  
  recipes, 368–369  
  troubleshooting, 368  
Stem cells. *See also* Hematopoietic stem cells (HSCs)  
  culturing adult stem cells from mouse small intestinal crypts (protocol), 417–421  
  discussion, 419–420  
  materials, 417–418  
  method, 418–419  
  culture of isolated crypts, 418–419  
  dissociation and culture of single cells, 419  
  isolation of crypts, 418  
  recipes, 420  
  ES cell rederivation, generation of multiallelic nGEMMs via, 197–198  
  history of use, 4–5  
  murine stem cell-based retrovirus  
    production for marking primary mouse mammary cells for metastasis studies (protocol), 364–369  
  reconstitution of mice with modified liver stem cells (protocol), 215–218  
    discussion, 217  
    materials, 215–216  
    method, 216–217  
    generation of genetically defined liver carcinomas, 217  
    purification, culture, and retroviral infection of hepatoblasts, 216–217  
    tumor retransplantation, 217  
    recipes, 218  
  Stem cell supplement (5×) (recipe), 213  
  Stewart, Timothy, 4, 5  
  Stochastic knock-in mouse models, 93  
  Stop elements, removal, 93–95, 94f  
  Strains. *See* Inbred mouse strains  
  Structured reporting in pathology for coclinical trials, 467–478  
    caELMIR example, 467, 468, 470–477  
    Experiment, 471, 472f, 473, 473f  
    pathology, 473  
    slide report, 473, 476f  
    Specimen, 473, 474f, 475f  
    spreadsheet report, 473, 477f  
    Study, 471, 471f, 472f  
    controlled vocabulary, 469–470  
    structured reports, 468–469  
  Subcapsular transplantation of tissue in the kidney (protocol), 268–271  
    discussion, 271  
    materials, 268–269  
    method, 269–270  
    troubleshooting, 270  
  Surfactant protein C (*SP-C*) promoter, in tetracycline-regulated model system, 131  
Surgery  
  abdominal laparotomy, acquisition of mouse tumor biopsies through (protocol), 440–449  
  anesthesia for, 443, 447–448  
  Survival study, 429  
  SV40 (simian virus 40), 3, 18–19, 458  
  SVDEs (scientifically validated data elements), 468–469, 478  
  SVMerge (software tool), 492  
  SV-MGH mice, 3  
  Syngeneic tumor graft model, 83f, 84  
  Synonymy, 469, 470  
  Synoptic reports, 468  
  Systematized Nomenclature of Human and Veterinary Medicine-Clinical Terms (SNOMED CT), 470  
**T**  
TALENs. *See* Transcription activator-like effector nucleases  
Tamoxifen  
  estrogen receptor (ER) regulatable system and, 111, 143–153  
  *Sleeping Beauty* transposon-based insertional mutagenesis and, 181–183, 182f  
  tamoxifen administration to mice (protocol), 151–152  
T1 and T2 values, diffusion tensor imaging and, 329, 341  
T-antigens, SV40, 18–19  
Target validation, GEMM use in, 8  
T-cell suspension assay (protocol), 396–400  
  discussion, 400  
  materials, 396–397  
  method, 397–400  
  isolation of Gr-1<sup>+</sup> cells, 398–399  
  plate setup, 399t  
  preparation of single-cell suspensions from spleens, 397–398  
  preparation of single-cell suspensions from tumors, 398  
  T-cell suspension assay, 399–400, 399t  
  troubleshooting, 400  
*tcf2a* gene, 147  
*Tcl1/mariner* elements, 174, 179  
Telly's combination fixative, 298, 298t  
Temperature support  
  during imaging, 327  
  during surgery, 446  
Terminologies, controlled, 469–470  
Test by transplantation, 280  
Tet operator (*TetO*), 111, 125, 126f, 127–128, 128f, 368  
Tetracycline-inducible shRNA against *p53*, 193  
Tetracycline-regulated systems, 125–142  
  future applications, 138  
  modeling cancer in vivo, 133–138, 134f  
  carcinogen-induced models, 137  
  cooperation between oncogenic signals, 136  
  metastasis, 136–137  
  oncogene addiction and cancer recurrence, 134–136  
  preclinical testing, 137–138  
  oncogenes for metastasis studies, 352  
  overview of, 125–127, 126f  
  RCAS-TVA system and, 128  
  *Sleeping Beauty* transposon-based insertional mutagenesis and, 182f, 183  
  technical applications, 127–129, 128f  
  " Tet-Off " system, 125, 127, 132  
  " Tet-On " system, 125, 127, 129, 132  
  tissue-specific model systems, 129–133  
    central nervous system, 131t, 133  
    colon, 131t, 132  
    hematopoietic, 130t, 133  
    liver, 130t, 132  
    lung, 130t, 131–132  
    mammary gland, 129, 131t  
    pancreas, 131t, 132  
    skin, 130t, 132–133  
    table of models, 130t–131t  
    thyroid, 131t, 132  
  Tetracycline transactivator (tTA), 125, 126f, 127  
  in metastasis studies, 352, 364, 368  
Tetraspanin CD151, 349  
Tet-responsive element (TRE), 97  
TGF-β  
  metastasis and, 349  
  signaling, 43–44  
Therapeutic trials/studies  
  goals and uses of studies in mice, 427–428

- infrastructure, 461–466
    - coclinical evaluation, 465–466
    - data integration, 465–466
    - education and training, 466
    - experimental design and treatment protocols, 464–465, 464b
    - Good Laboratory Practice, 464
    - housing and husbandry, 462
    - mouse hospital, 463b, 463f
    - mouse pharmacy, 462–463, 463b
    - overview, 462, 464
    - preclinical, 434–435
    - standard operating procedures (SOPs), 462, 464
  - interpretation of trial outcomes, 430–431
  - practical considerations in study design, 431–432
    - dose and schedule, 431–432
    - enrollment criteria, 431
    - length of treatment, 432
    - routes of drug delivery, 432
    - tumor monitoring, 432
  - reasons for performing clinical trials in GEMMs, 436–437
    - resistance to cancer therapies, 436
    - testing efficacy of new therapeutic agents, 436
    - tumor microenvironment and response to drugs, 436–437
  - techniques used in, 433–434
    - immunohistochemical markers used to assess therapy response, 433t
    - pharmacodynamics and pharmacokinetic measurements, 433–434
    - tumor biopsies, 434
  - trial structures, 429–430
    - intervention trials, 430
    - phenotypic end point study, 429
    - prevention trials, 429–430
    - survival study, 429
    - time-point study, 429
  - Thymidine kinase from herpes simplex virus (*HSV1-tk*), 316
  - Thyroid cancer, tetracycline-regulated model system for, 131t, 132
  - TICS (tumor-initiating cells), 259–261, 259t
  - Time-point study, 429
  - Tissue biopsy. *See* Biopsy
  - Tissue dissociation for metastatic studies (protocol), 358–363
    - counting cells, 360
    - discussion, 361
    - dissociation of tissue, 359–360
    - mammary cell culture and viral transduction, 360
    - materials, 358–359
    - method, 359–360
    - recipes, 362
    - troubleshooting, 361
  - Tissue recombination models for study of epithelial cancer, 227–251
    - mammary fat pad as an orthotopic site for studying breast cancer, 229–230
    - mimicking the native tumor microenvironment, 230–231, 232f–233f
    - overview, 227–228
    - protocols, 240–251
      - cleared mammary fat pad transplantation assay for mammary epithelial organogenesis, 247–251
      - cleared MFP transplantation, 249–250, 250f
      - dissociation of mouse mammary tissue, 248–249, 249f
      - materials, 247–248
      - method, 248–250, 249f, 250f
      - recipes, 250–251
    - dissociated prostate regeneration under the renal capsule, 243–246
    - dissociation of mouse prostate tissues, 244
    - engraftment of prostate cell recombinants into subrenal capsules, 245
    - materials, 243–244
    - method, 244–245
    - preparation of prostate cell recombinants in collagen plugs, 245
    - recipes, 246
    - troubleshooting, 245
  - preparation of urogenital sinus mesenchymal cells for prostate tissue recombination models, 240–242
    - materials, 240–241
    - method, 241
    - recipe, 242
  - strategies to convert benign human epithelia to cancer, 235–236
  - strengths and weaknesses of, 231–235
  - tumor xenografts grown in orthotopic versus subcutaneous sites, 228–229
- Tissue reconstitution, 203–226
  - chimeric models to study liver cancer, 205
  - ex vivo manipulation of hematopoietic stem cells (HSCs), 204
  - genetic screens in transplant models, 206–207
  - loss-of-function screening in hematopoietic malignancies (protocol), 224–226
    - discussion, 226
    - materials, 224
    - method, 224–226, 225f
    - assessing tumor engraftment efficiency, 225
    - deconvoluting shRNA representation, 225–226
    - reconstituting mice with modified liver stem cells, 225
  - troubleshooting, 226
  - organ systems amenable to reconstitution, 204
  - overview, 203–204
  - reconstitution of mice with modified HSCs (protocol), 209–214
    - discussion, 212–213
    - materials, 209–210
    - method, 210–212, 210f
    - infection, 211
    - injection, 212
    - isolation of HSCs from bone marrow, 211
    - isolation of HSCs from fetal liver, 210–211
    - recipes, 213–214
    - troubleshooting, 212
  - reconstitution of mice with modified liver stem cells (protocol), 215–218
    - discussion, 217
    - materials, 215–216
    - method, 216–217
    - generation of genetically defined liver carcinomas, 217
    - purification, culture, and retroviral infection of hepatoblasts, 216–217
    - tumor retransplantation, 217
      - recipes, 218
    - RNAi use in vivo, 205
    - synergic transplants with modified chimeric hematopoietic tumors (protocol), 219–223
      - discussion, 222, 222f
      - materials, 219–220
      - method, 220–221
      - recipes, 222–223
      - troubleshooting, 221–222
    - using transplant models to study cancer therapy, 206
  - Titf1/Nkx2-1, 480
  - TKIs. *See* Tyrosine kinase inhibitors (TKIs)
  - Tol2* transposon-based insertional mutagenesis, 180
  - T2/Onc2 and T2/Onc3* transposon, 176, 179
  - TopHat algorithm, 492
  - Topoisomerase I, 206
  - Topoisomerase II, 206
  - Toxic compounds, 504
  - TPA (12-*O*-tetradecanoylphorbol-13-acetate), 54, 55
  - TRAMP metastatic prostate cancer model, 351, 482
  - Transcription activator-like effector nucleases (TALENs), 98, 99f, 100–101, 199
  - Transcriptional terminal stop elements, removable, 93–95, 94f
  - Transformation related protein 53 (*Trp53*), 147, 148f, 179, 181. *See also* p53
    - Sleeping Beauty* mutagenesis and, 179, 181
    - TP53* knock-in models of cancer, 90, 92t
  - Transgenic mouse models, early, 17–24
    - brain tumors induced by SV40 large T-antigen, 18–20
    - of breast cancer, 20–21
    - of Burkitt's lymphoma, 22
    - elastase-promoter-driven models, 23
    - $\text{E}\mu$ -Myc model, 22
    - mouse mammary tumor virus (MMTV), 20–21
    - overview, 17–18
    - RIP-Tag, 23
    - time line of model development, 19f
    - with tissue-specific oncogene expression, 21–23
    - with viral promoter/enhancer-driven oncogenes, 21–22
  - Translational therapeutics, 427–453. *See also* Therapeutic trials/studies
    - acquisition of mouse tumor biopsies through abdominal laparotomy (protocol), 440–449
      - discussion, 446–449
      - evaluation of tumor location and vascularity, 447
      - KPC model of pancreatic ductal adenocarcinoma (case study), 446–447
      - mouse anesthesia, 447–448
      - outcome, 448–449, 448f
      - materials, 440–442, 442f
      - method, 442–446
      - advance preparation, 442–443, 443f
      - animal preparation, 443–444
      - postoperative care, 445–446
      - surgery, 444–445, 444f
      - troubleshooting, 446
    - example trials in GEMMs, 437t
    - features of translational mouse model, 428–429

## Index

- Translational therapeutics (*Continued*)  
  generation of drug-resistant tumors using  
    intermittent dosing of tyrosine kinase inhibitors in mice (protocol), 450–453  
    discussion, 452, 452f  
    materials, 450–451  
    method, 451  
    recipe, 452–453  
    troubleshooting, 451  
  goals and uses of studies in mice, 427–428  
  interpretation of trial outcomes, 430–431  
  practical considerations in study design, 431–432  
    dose and schedule, 431–432  
    enrollment criteria, 431  
    length of treatment, 432  
    routes of drug delivery, 432  
    tumor monitoring, 432  
  preclinical infrastructure, 434–435  
  reasons for performing clinical trials in GEMMs, 436–437  
    resistance to cancer therapies, 436  
    testing efficacy of new therapeutic agents, 436  
    tumor microenvironment and response to drugs, 436–437  
  techniques used in studies, 433–434  
    immunohistochemical markers used to assess therapy response, 433t  
    pharmacodynamics and pharmacokinetic measurements, 433–434  
    tumor biopsies, 434  
  therapeutic trial structures, 429–430  
    intervention trials, 430  
    prevention trials, 429–430  
Transplantation  
  orthotopic, 228–229  
  subcapsular transplantation of tissue in the kidney (protocol), 268–271  
    discussion, 271  
    materials, 268–269  
    method, 269–270  
    troubleshooting, 270  
  tissue recombination models for study of epithelial cancer, 227–251  
    cleared mammary fat pad transplantation assay for mammary epithelial organogenesis (protocol), 247–251  
    cleared MFP transplantation, 249–250, 250f  
    dissociation of mouse mammary tissue, 248–249, 249f  
    materials, 247–248  
    method, 248–250, 249f, 250f  
    recipes, 250–251  
    dissociated prostate recombinants under the renal capsule (protocol)  
    engraftment of prostate cell recombination into subrenal capsules, 245  
    materials, 243–244  
    method, 244–245  
    preparation of prostate cell recombinants in collagen plugs, 245  
    recipes, 246  
    troubleshooting, 245  
    dissociated prostate regeneration under the renal capsule (protocol), 243–246  
    dissociation of mouse prostate tissues, 244  
    mammary fat pad as an orthotopic site for studying breast cancer, 229–230  
    mimicking the native tumor microenvironment, 230–231, 232f–233f  
    overview, 227–228  
    preparation of urogenital sinus mesenchymal cells for prostate tissue recombination models (protocol), 240–242  
    materials, 240–241  
    method, 241  
    recipe, 242  
    protocols, 240–251  
    strategies to convert benign human epithelia to cancer, 235–236  
    strengths and weaknesses of models, 231–235  
    tumor xenografts grown in orthotopic versus subcutaneous sites, 228–229  
Transposase, 173–174  
Transposon-based insertional mutagenesis, 173–184  
  future of, 182–183  
  *Minos*, 179–180  
  overview, 173–174  
  PCR amplification and sequencing of transposon insertion sites, 176–177, 177f  
*PiggyBac*, 180–181  
*Sleeping Beauty*  
  applications of, 176  
  hallmarks of *Sleeping Beauty*-driven tumors, 181  
  to identify genetic determinants of drug resistance in cancer, 183  
  induction of mutagenesis, 178  
  modeling solid tumors using, 178–179  
  overview, 174–176  
  refinements of system, 181–183, 182f  
  transposon and transposase alleles, 175t  
*Tol2*, 180  
Transposons  
  concatenation of, 173  
  copy number, 173, 176  
  mobilization of, 173  
  PCR amplification and sequencing of transposon insertion sites, 176–177, 177f  
TRE (tet-responsive element), 97  
TRE promoter, 194  
Trials. *See also* Therapeutic trials/studies  
  Co-Clinical Trial Project, 10–12, 10f, 11f  
  designing preclinical, coclinical, and postclinical trials, 459–460  
    clinically relevant end points, 460  
    imaging, 459  
    pharmacokinetics/pharmacodynamics, 459  
    relevance to ongoing clinical trials, 459  
    statistical power, 459  
    tissue collection, pathology, and bioinformatics, 460  
  GEMMs use in, 455–460  
    designing preclinical, coclinical, and postclinical trials, 459–460  
    goals for clinical efforts in GEMMs, 457b  
    optimizing model use for preclinical, coclinical, and postclinical trials, 456–457, 456b  
    selecting appropriate model for analyses, 457–459  
  infrastructure needs for, 461–466  
    coclinical evaluation, 465–466  
    data integration, 465–466  
    education and training, 466  
    experimental design and treatment protocols, 464–465, 464b  
    Good Laboratory Practice, 464  
    housing and husbandry, 462  
    mouse hospital, 463b, 463f  
    mouse pharmacy, 462–463, 463b  
    overview, 462, 464  
    standard operating procedures (SOPs), 462, 464, 465  
  preclinical drug testing, 7–9  
  structured reporting in pathology for coclinical trials, 467–478  
    caELMIR example, 467, 468, 470–477  
    Experiment, 471, 472f, 473, 473f  
    pathology, 473  
    slide report, 473, 476f  
    Specimen, 473, 474f, 475f  
    spreadsheet report, 473, 477f  
    Study, 471, 471f, 472f  
    controlled vocabulary, 469–470  
    structured reports, 468–469  
*Trp53*. *See* Transformation related protein 53  
Trypan blue viability, for counting viable cells, 360, 373  
Trypsin, for digestion of urogenital sinus, 241  
Trypsin-EDTA (recipe), 407, 411  
Trypsin-EDTA in PBS (recipe), 415  
tTA (tetracycline transactivator), 125, 126f, 127  
  in metastasis studies, 352, 364, 368  
Tumor-initiating cells (TICS), 259–261, 259t  
Tumor monitoring, in therapeutic trials/studies, 432  
Tumor suppressors  
  analyses in germline mouse models of cancer, 27–31  
    *Apc*, 30  
    benefits of, 28  
    *Brc1/2*, 31  
    *Ink4a*, 30–31  
    lessons learned from, 28t  
    *Nf1/2*, 30  
    *p27(Kip1)*, 31  
    *p53*, 28–29  
    *Pten*, 29–30  
    *RB*, 29  
    ER-fused tumor suppressors, 147–149, 148f  
    hypermethylation of CpG islands in promoters, 482  
  Tumor virus A (TVA) receptor, 155–160  
  2A peptide, 98  
  Tyrosine kinase inhibitors (TKIs)  
    EGFR and, 432, 436, 452  
    generation of drug-resistant tumors using intermittent dosing in mice (protocol), 450–453  
    discussion, 452, 452f  
    materials, 450–451  
    method, 451  
    recipe, 452–453  
    troubleshooting, 451  
  Tyrosine (*Tyr*) promoter, in tetracycline-regulated model system, 133
- ## U
- Ubiquitin-specific protease 6 (*USP6*), 494  
UCSC LiftOver tool, 494  
Ultrasonicators, 500–501



- Ultrasound imaging, 326t, 331–332  
  color Doppler, 447  
  for evaluating pancreatic tumors, 446  
  nonlinear contrast ultrasound, 447  
  of pancreatic ductal adenocarcinoma, 443f  
  power Doppler, 447
- U6 promoter, 189
- Urethane  
  induction of lung tumors in mice  
    with urethane (protocol), 63–65, 64f  
  metabolic activation of, 53  
  use to identify lung cancer susceptibility loci, 56
- Urogenital sinus mesenchyme (UGSM), 230, 232f  
  fibroblast growth factor 10 (FGF10)  
    overexpression, 235  
  preparation of urogenital sinus mesenchymal cells for prostate tissue recombination models (protocol), 240–242  
  materials, 240–241  
  method, 241  
  recipe, 242
- Urokinase, 349
- V**
- VarScan 2 algorithm, 492
- Vascular endothelial cadherin promoter (*VECad*), 146
- Vasculature, evaluation of tumor, 447
- VECad*-Cre-ER<sup>T2</sup>, 146
- Vectastain ABC Reagent, 393
- VEGFR, 9
- Via-Probe fluorescence, 387
- Viral delivery of Cre  
  in vivo delivery of lenti-Cre or adeno-Cre into mice using intranasal instillation (protocol), 119–121  
  in knock-in mouse models, 96  
  overview, 111–112  
  producing and concentrating lenti-Cre for mouse infections (protocol), 116–118  
  materials, 116–117  
  method, 117–118  
  materials, 119–120  
  method, 120  
  recipe, 121  
  troubleshooting, 120–121
- Vocabulary, controlled, 469–470
- v-Src*, 3
- VSV-G-pseudotyping, 221
- W**
- Wagner, Erwin, 21
- WAP-Cre, 35, 37, 40, 42
- Waste, disposal of, 501, 502
- WEHI conditioned medium (recipe), 214
- Weinberg, Robert, 5
- Whey acidic protein (*WAP*) promoter, 21  
  in tetracycline-regulated model system, 129  
  WAP-Cre, 35–36, 40, 42
- Whole-slide imaging (WSI), 289–290, 290t
- Wilms' 1 (WT1) tumor antigen, 258
- Wnt1* gene, enhancer of, 145
- Wong, Kwok Kin, 11
- X**
- X chromosome, variation across mouse strains, 71
- Xenografts, 9
- X-gal rinse buffer for Cre expression (recipe), 124
- X-gal solution (recipe), 124
- X-gal staining of whole-mount mouse tissues (protocol), 122–124  
  materials, 122–123  
  method, 123  
  recipes, 124  
  troubleshooting, 123
- Y**
- Y chromosome, polymorphisms in, 71
- Z**
- Zeb1, 376
- Zinc-finger nucleases (ZFNs), 98, 99f, 100–101